Open Access

‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 1: Anti-mGluR1, anti-Homer-3, anti-Sj/ITPR1 and anti-CARP VIII

Journal of Neuroinflammation201512:166

https://doi.org/10.1186/s12974-015-0356-y

Received: 15 May 2015

Accepted: 2 July 2015

Published: 17 September 2015

Abstract

Serological testing for anti-neural autoantibodies is important in patients presenting with idiopathic cerebellar ataxia, since these autoantibodies may indicate cancer, determine treatment and predict prognosis. While some of them target nuclear antigens present in all or most CNS neurons (e.g. anti-Hu, anti-Ri), others more specifically target antigens present in the cytoplasm or plasma membrane of Purkinje cells (PC). In this series of articles, we provide a detailed review of the clinical and paraclinical features, oncological, therapeutic and prognostic implications, pathogenetic relevance, and differential laboratory diagnosis of the 12 most common PC autoantibodies (often referred to as ‘Medusa-head antibodies’ due to their characteristic somatodendritic binding pattern when tested by immunohistochemistry). To assist immunologists and neurologists in diagnosing these disorders, typical high-resolution immunohistochemical images of all 12 reactivities are presented, diagnostic pitfalls discussed and all currently available assays reviewed. Of note, most of these antibodies target antigens involved in the mGluR1/calcium pathway essential for PC function and survival. Many of the antigens also play a role in spinocerebellar ataxia. Part 1 focuses on anti-metabotropic glutamate receptor 1-, anti-Homer protein homolog 3-, anti-Sj/inositol 1,4,5-trisphosphate receptor- and anti-carbonic anhydrase-related protein VIII-associated autoimmune cerebellar ataxia (ACA); part 2 covers anti-protein kinase C gamma-, anti-glutamate receptor delta-2-, anti-Ca/RhoGTPase-activating protein 26- and anti-voltage-gated calcium channel-associated ACA; and part 3 reviews the current knowledge on anti-Tr/delta notch-like epidermal growth factor-related receptor-, anti-Nb/AP3B2-, anti-Yo/cerebellar degeneration-related protein 2- and Purkinje cell antibody 2-associated ACA, discusses differential diagnostic aspects and provides a summary and outlook.

Keywords

Autoimmune cerebellar ataxia Cerebellitis Paraneoplastic cerebellar degeneration Autoantibodies Purkinje cells Metabotropic glutamate receptor 1 (mGluR1) antibodies Homer-3 antibodies Anti-Sj Inositol 1,4,5-trisphosphate receptor 1 (ITPR1, I3PR) antibodies Carbonic anhydrase-related protein VIII (CARP VIII) antibodies Protein kinase gamma (PKCγ) antibodies Anti-Ca Rho GTPase-activating protein 26 (ARHGAP26, GRAF) antibodies Glutamate receptor delta2 (GluRδ2) antibodies Anti-Yo Cerebellar degeneration-related protein 2 (CDR2) antibodies Cerebellar degeneration-related protein 2-like (CDR2L) antibodies Purkinje cell antibody 2 (PCA-2) Anti-Tr Delta notch-like epidermal growth factor-related receptor (DNER) antibodies Anti-Nb Anti-AP3B2 Neuronal adaptin-like protein (beta-NAP) antibodies Voltage-gated calcium channel (VGCC) antibodies

Introduction

Autoimmune cerebellar ataxia (ACA) is an important differential diagnosis in patients presenting with signs and symptoms of cerebellar disease. Alongside multiple sclerosis and acute disseminated encephalomyelitis, autoantibody-associated disorders of the CNS are the most common cause of ACA. While ACA is a rare manifestation in some of these disorders, e.g. aquaporin-4 (AQP4) antibody-associated neuromyelitis optica (NMO), it is the most frequent or exclusive presentation in others. To date, around 30 different autoantibodies targeting brain antigens have been reported in patients with ACA, many of which are of paraneoplastic origin (Table 1).
Table 1

Selected antibodies to cerebellar antigens reported in patients with cerebellar ataxia

Target structures

Comments

Ref

Purkinje cells

  

MGluR1/calcium pathway-related

  

  Anti-mGluR1

Tumour-associated in some cases

[3336]

  Anti-Homer-3

Lung cancer-associated in one unpublished cases

[85, 86]

  Anti-Sj/ITPR1

NSCLC-associated in one unpublished case

[100]

  Anti-CARP VIII

Reported in association with melanoma and ovarian cancer

[134, 135]

  Anti-PKCγ

Reported in association with SCLC and liver cancer

[147, 148]

  Anti-GluRδ2

Mostly para/postinfectious

[149151]

  Anti-Ca/ARHGAP26

Tumour-associated in a few cases

[74, 152, 153]

  Anti-P/Q-type VGCC

Tumour-associated in many cases

[13, 14]

  Anti-N type VGCC

Often associated with anti-P/Q-type VGCC

[154157]

  Anti-Yo/CDR2 (PCA-1)a

Typical paraneoplastic syndrome

[15, 158162]

  Anti-Nb/AP3B2/beta-NAP

Tumour-association unknown

[163, 164]

Others

  

  PCA-2 (target antigen not known)

Tumour-associated in almost all published cases

[154]

  Anti-Tr/DNER

HD-associated in almost all cases

[165169]

Molecular and granular layer, PCs spared

  

 Anti-amphiphysin

Tumour-associated in most cases

[170]

 Anti-GABABR

Tumour-associated in many cases

[5052]

 Anti-DPPX

Reported in association with B cell neoplasm in a few patients

[171174]

 Anti-Caspr2

Facultatively paraneoplastic

[175, 176]

Pinceau formation/Basket cells

  

 Anti-LGI1

Mainly not tumour-associated

[177]

Granular layer

  

 Anti-GAD

DM-associated (mostly DM type I) and, in neurological patients, often tumour-associated

[119, 178181]

Oligodendrocytes

  

 Anti-CV2/CRMP5

Typical paraneoplastic syndrome

[182184]

 Anti-MOG

Usually non-paraneoplastic

[185, 186]

Astrocytic endfeet

  

 Anti-AQP4

Very rarely causing cerebellar ataxia, usually non-paraneoplastic

[187, 188]

Neuronal nuclei

  

 ANNA-1 (Anti-Hu/HuD)

Neuronal nuclei in the CNS and PNS paraneoplastic

[189191]

 ANNA-2 (Anti-Ri)

Neuronal nuclei in the CNS paraneoplastic

[192, 193]

 ANNA-3 (unknown antigen)

Typical paraneoplastic syndrome

[194]

 Anti-Zic4

Typical paraneoplastic syndrome

[195, 196]

 Anti-Zic2

Mostly SCLC-associated

[197]

 Anti-Zic1

Mostly SCLC-associated

[197]

Bergman glial cell nuclei

  

 AGNA/Anti-SOX1b

Typically tumour-associated

[198, 199]

Nucleoli

  

 Anti-Ma2/Ta (PNMA2)

Typical paraneoplastic syndrome

[200, 201]

 Anti-Ma1 (PNMA1)

Typical paraneoplastic syndrome

[200, 201]

Centrosome

  

 Anti-γγ-enolase, -pericentrin, -ninein, -PCM1, -Mob1

Para-/post varicella zoster virus

[202]

Centriols

  

 Anti-centriolar antibodies

Para-/post M. pneumoniae

[203]

Others

  

 Anti-transglutaminase6

Associated with celiac disease

[204, 205]

 Anti-triophosphate isomerase

Post-EBV

[206]

 Anti-20 S proteasome

Associated with anti-Yo

[207]

 Anti-GQ1b

‘Ataxic Guillaine Barré syndrome’

[208211]

DM diabetes mellitus, HD Hodgkin’s disease

aFurther target antigens reported in the literature: CDR34, CDR3, CDR2L

bWhether AGNA and SOX1 are identical is controversial; recent evidence suggests that they may represent different reactivities

When tested by immunohistochemistry (IHC) using cerebellum tissue sections, some of these antibodies (anti-metabotropic glutamate receptor 1 (mGluR1), anti-Homer protein homolog 3 (Homer-3), anti-Sj/inositol 1,4,5-trisphosphate receptor (ITPR1), anti-carbonic anhydrase-related protein VIII (CARP VIII), anti-protein kinase C gamma (PKCγ), anti-Ca/RhoGTPase-activating protein 26 (ARHGAP26), anti-glutamate receptor delta 2 (GluRδ2), anti-Tr/delta notch-like epidermal growth factor (EGF)-related receptor (DNER), voltage-gated calcium channels (VGCC) antibodies, anti-Nb/AP3B2, anti-Yo/cerebellar degeneration-related protein 2 (CDR2) and Purkinje cell antibody 2 (PCA-2)) show a staining pattern resembling a Gorgon’s head, caused by binding of IgG to Purkinje cell (PC) somata and dendrites and are therefore often referred to as ‘Medusa head’ antibodies (Fig. 1).
Fig. 1

Medusa-head ataxia. a Detail from Sir Peter Paul Ruben’s (1577–1640) famous painting of a gorgon head (dated 1617/1618; Kunsthistorisches Museum, Vienna, Austria). b A drawing of a Purkinje cell by the Spanish pathologist, histologist, neuroscientist, and Nobel laureate Santiago Felipe Ramón y Cajal (1852–1934). c Purkinje cells somata and dendrites stained by IgG from a patient with autoimmune cerebellar ataxia

Due to their similar binding patterns, it can be very difficult to differentiate the members of the expanding family of somatodendritic or ‘Medusa head’ PC antibodies. Here, we show exemplary IHC findings for each of these antibodies, review the currently available diagnostic assays, and discuss diagnostic pitfalls. In addition, we provide a comprehensive summary of the clinical, paraclinical and epidemiological features associated with these antibodies, briefly review the available knowledge regarding their pathophysiological relevance and discuss their oncological and prognostic implications.

The present, first article in this series will review the current knowledge on anti-mGluR1-, anti-Homer-3-, anti-Sj/ITPR1- and anti-CARP VIII-positive ACA.

Antibodies targeting antigens involved in the glutamate/calcium pathway

Interestingly, most of the antigens so far identified in patients with ‘Medusa head’ antibodies—namely mGluR1, Homer-3, ITPR1, CARP VIII, PKCγ, GluRδ2, VGCC, CDR2-like (CDR2L), neuronal adaptin-like protein (beta-NAP) and possibly also ARHGAP26 and CDR2—are functionally and structurally related in that all are involved in the PC phosphatidylinositol-calcium second messenger system or, more generally, in maintaining intracellular calcium homeostasis: In the cerebellum, release of glutamate, the major excitatory neurotransmitter in the CNS, by parallel fibre (PF) (and possibly climbing fibre (CF)) [1] synapses stimulates postsynaptic mGluR1, which is the main metabotropic receptor on PCs. At the PC/PF synapse, this results in cleavage of phosphatidyl 4,5-bisphosphate (PIP2) by phospholipase Cβ3 (PLCβ3), the target of the G proteins of mGluR1, into diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). IP3 acts as a second messenger for ITPR1, a calcium channel mainly located in the membrane of the smooth endoplasmic reticulum (ER) and physically linked to mGluR1 via Homer-3 [1]. Upon activation by IP3, ITPR1 mediates intracellular Ca2+ release from the ER calcium storage [1]. CARP VIII, on the other hand, limits Ca2+ efflux from the ER by reducing the affinity of ITPR1 for IP3 [2]. Intracellular calcium together with DAG activates PKCγ [3], a protein kinase involved in calcium regulation by its capability to phosphorylate and thus inactivate the DAG-activated canonical transient receptor potential (TRPC) type 3 cation channel 3 [46], resulting in reduced influx of calcium ions [7]. GluRδ2 has been recently shown to associate with mGluR1, PKCγ and TRPC3 [5, 6, 810] and to regulate mGluR1-mediated synaptic transmission in PCs. ARHGAP26 has been found to precipitate with dynamin, which is involved in mGluR1 internalisation [11, 12]. Blockade of CDR2 by anti-Yo autoantibodies has been reported to induce the expression of PKCγ and the pore- and gating apparatus-forming VGCC protein Cav2.1, which is an autoantigen in ACA itself [13, 14], and also to regulate the expression of several other calcium-related proteins [15]. Finally, mGluR1a interacts directly with Cav2.1, forming a heteromeric protein complex [1618] and has been shown to inhibit Cav2.1-mediated Ca2+ currents [16, 19, 20].

Of note, mutations in almost all of the components of the mGluR1 cascade have been demonstrated to cause cerebellar ataxia either in humans or in animal models. Homozygous mutations in the GRM1 gene encoding mGluR1 underlie spinocerebellar ataxia (SCA) 13 [21]. Gq mutant PCs remain multiply innervated by CFs and are associated with impaired motor coordination in adult mice [22, 23]. Phospholipase C mutant mice show deficient long-term synaptic depression and impaired motor learning [24]. Mutations in the ITPR1 gene have been found to cause SCA15 and 21 [25]. Missense mutations in the PKCγ gene have been found in SCA14 [26], and loss of PKCγ also seems to play a role in SCA1 [27]. Mice deficient in TRPC3 exhibit impaired walking behaviour [5]. Mutations in beta-3 spectrin influencing glutamate receptor GluRδ2 expression as well as deletions in the GRID2 gene itself have recently been discovered in SCA5 and other forms of hereditary cerebellar ataxia in humans [28, 29]. Finally, mutations in the Cav2.1 gene cause SCA6 [3032].

All sections dealing with individual antibody reactivities are structured uniformly to improve accessibility of the information provided. Each section consists of an identically headed set of subsections dealing with (1) clinical, paraclinical and epidemiological features associated with the respective antibody; (2) associated tumours; (3) syndrome outcome and prognosis; (4) target antigen structure and function; (5) diagnostic IHC findings; (6) antigen-specific assays; (7) relevance of CSF testing; (8) association with other autoantibodies; (9) evidence for a pathogenic role of the antibody; and (10) molecular genetics, inasmuch as they corroborate a potential role of the target antigen in cerebellar ataxia.

Anti-mGluR1

Clinical, paraclinical and epidemiological features

Since the first description of anti-mGluR1 in 2000, five patients have been reported (three female, two male; median age 50 years, range 19–69) [3336], all of whom presented with cerebellar gait ataxia (partly unable to walk without help) and limb ataxia (dysmetria of arms and/or legs, intention tremor). Further symptoms included trunk ataxia (partly unable to sit without help, head titubation, truncal sway) in four, dysarthria in four, and ocular symptoms (nystagmus, oscillopsia, diminution in speed of saccades, impaired adaptation of saccadic eye movements, difficulty directing and maintaining fixation of gaze, slight opsoclonus) in all cases. While a subacute onset was noted in two, symptoms worsened slowly in two other patients (no data in one). Magnetic resonance imaging (MRI) showed cerebellar atrophy in two patients [34, 36] and diffuse abnormal hyperintensity in the whole cerebellum present only on fluid-attenuated inversion recovery and diffusion sequences in another case [35], but was normal in the remaining two (follow-up for up to 6 months). Lumbar puncture revealed mononuclear pleocytosis in three patients (9, 28, and 190 cells/μl) and was normal in one (no data in one case); signs of intrathecal IgG synthesis were present in one of two patients examined. Additional cases of ACA and mGluR1 have been identified at the authors’ institution and elsewhere, but no additional clinical information is currently available.

Given that mGluR1 is expressed widely throughout the CNS, it is not surprising that two patients developed signs of encephalitis in addition to ataxia, including mild cognitive decline in one case and short-term memory loss in the other.

Association with tumours

In three out of five cases, anti-mGluR1 autoantibodies were associated with malignant tumours. The two index patients had a history of nodular sclerosing Hodgkin’s disease (HD) but had been in remission for 2 and 9 years, respectively, at the time of onset of anti-mGluR1-associated ACA; however, mGluR1 was not detected in a tumoral lymph node from one of those patients, and no tumour specimen was analysed in the second case, rendering it unclear whether the two conditions were pathophysiologically related [33]. Sera from patients with Hodgkin’s lymphoma but no cerebellar ataxia did not show anti-mGluR1 [33]. A third patient had an adenocarcinoma of the prostate, which was only discovered 20 months after onset of the cerebellar ataxia, as well as a history of a successfully treated cutaneous T cell lymphoma. In contrast to the index cases, mGluR1 was found to be abundantly present in the tumour tissue and binding of the patient’s IgG to tumoral mGluR1 could be demonstrated [34]. Two patients did not show any evidence of a tumour up to 40 months after onset [35, 36].

Outcome and prognosis

While treatment with steroids, plasma exchange (PEX), intravenous immunoglobulins (IVIG) and oral steroids was followed by slow yet complete recovery in index patient 1; PEX did not result in significant improvement in the second patient, who remained unable to walk without support. Hodgkin’s disease remained in complete remission in both cases [33]. In a third patient, commencement of treatment with steroids, IVIG and mycophenolate mofetil early in the disease course led to continuous clinical improvement and a drop in anti-mGluR1 serum titres (1:20,000 to 1:500). At last follow-up, 40 months after onset, the patient was still able to walk [35]. In patient 4, a transient improvement was noted after intravenous methylprednisolone (IVMP); however, subsequent courses of IVMP were not followed by further improvement, and severe and disabling ataxia and dysarthria were present at last follow-up [36]. In patient 5, treatment of the prostate carcinoma was associated with severe neurological deterioration; later on, sustained improvement was achieved after treatment with IVIG and low-dose steroids [34].

Antigen

MGluR1 (encoded by GRM1) is a cell surface receptor belonging to the guanine nucleotide-binding protein (G-protein)-activating receptor 3 family [37]. Its natural ligand is the excitatory neurotransmitter L-glutamate. Glutamate produces fast excitation through activation of ionotropic glutamate receptors (GluRs, including N-methyl D-aspartate (NMDA) receptors, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors and kainate (KA) receptors) and slower actions through metabotropic receptors (mGluRs). To date, eight mGluRs are known (mGluR1-8). Together with mGluR5, mGluR1 forms group I of the metabotropic glutamate receptors. So far, five isoforms of mGluR1 have been described [3739] with the canonical isoform alpha being a disulphide-linked homodimer primarily coupled to Gq/G11 [40] by which it is linked to the inositol phospholipid metabolism, i.e. it elicits an increase in the PIP2 turnover by activating PLCβ to hydrolyse PIP2 to IP3 and DAG, which results in intracellular calcium release from intracellular stores and activation of PKCγ. Besides classical, glutamate-stimulated activation, also agonist-independent, ‘constitutive’ activity of mGluR1 (and mGluR5) occurs, modulated by intracellular proteins including Homer-3 and Homer-1a [41].

The protein comprises an extracellular N-terminus containing the glutamate binding site, seven alpha-helical transmembrane domains and an (isoform-specific) cytoplasmic C-terminus—with the exception of isoform 1e, which is truncated before the first transmembrane domain. The G-protein-binding C-terminus contains domains that regulate mGluR1 function/signalling as well as its localisation and subcellular distribution in the dendritic membrane, its trafficking and its internalisation. Importantly, via a cytoplasmic Homer-binding PPxxFR motif, the receptor (more specifically, the long 1194-amino acid isoform 1a [42, 43]) binds Homer-3 (as well as Homer-1 and -2), another autoantigen in ACA, which regulates the postsynaptic localisation of mGluR1 as well as its activity [44].

In common with other mGluRs, the postsynaptic group I mGluRs transduce stimulatory signals at excitatory synapses. MGluR1 is present in the highest concentrations at the PF/PC synapse. Upon stimulation, the receptor modulates neuronal excitability by controlling ion channels. Modifications in the subcellular expression and distribution of mGluR1, together with changes induced by stimulation of mGluR1, participate in the long-term synaptic plasticity involved in memory formation and learning [37]. MGluR1 regulation is believed to have an important role in both types of long-term synaptic plasticity: while it has been implicated in long-term depression (LTD) of synaptic efficacy in the cerebellum, it is involved in long-term potentiation (LTP) in the hippocampus [4547].

The proteins with which mGluR1 is associated or interacts in the cerebellum, hippocampus or cerebral cortex include, among others, TRPC, a cation channel involved in slow excitatory cation conductance [5, 48], the P/Q-type voltage-gated calcium channel (VGCC) (Cav2.1) [16] and gamma-aminobutyric acid type B receptors [49], which are both known target autoantigens in patients with ACA themselves [13, 5052], NMDA receptors [53, 54], an important autoantigen in autoimmune encephalitis [55], and adenosine A1 receptor [56].

Outside the cerebellum, mGluR1 has been found in mitral and tufted cells of the olfactory bulb [57] and, at lower levels, in the hippocampus [58], the amygdala, the hypothalamus, where they take part in regulating circadian rhythms [59] and hormone secretion [60], the basal ganglia including the subthalamic nucleus, the thalamus, where it is involved in processing of nociception and pain and of other sensory information [6164], and the ventral horn, central grey, substantia gelatinosa and sensory trigeminal nuclei of the spinal cord, where it is also implicated in nociception, as well as in the cerebral cortex and brainstem [38, 65, 66]; mGluR1 has important physiological roles also in motor neurons [6769].

Immunohistochemistry

As indicated above, mGluR1 is widely expressed throughout the central nervous system, mostly postsynaptically in neuronal dendrites and somata [38, 70, 71]. Within the cerebellum, it is enriched in PCs, with the highest levels in the dendritic spines (Fig. 2) [38, 58, 65]; in addition, granular cells and other interneurons seem to express mGluR1 at lower RNA and protein levels [58, 66, 72, 73]. Makoff et al. [39] found mGluR1c exclusively in granule cells by in situ hybridisation, while an mGLUR1a/mGLUR1b probe reacted in addition with PCs and basket cells. Mateos et al. [71] found both mGluR1a and mGluR1b by immunogold labelling in the dendritic spines of PCs receiving PF synaptic terminals and reported additional peri-extrasynaptic mGluR1a/b expression.
Fig. 2

Expression of mGluR1 in the human cerebellum as demonstrated by IHC (modified image from the Human Protein Atlas image database [101])

Anti-mGluR1 autoantibodies were originally detected by avidin-biotin peroxidase and avidin Texas red IHC, respectively, using formalin-perfused sections of mouse and human cerebellum [33]. The patients’ sera strongly stained PC bodies and dendrites (but not the PC axons). Using confocal microscopy, a strong punctate staining in the molecular layer of the cerebellum was observed, indicative of labelling of the PC spines. Later studies used mouse, rat or primate brain sections (formalin fixed in three studies, not specified in another one) and either conventional IHC or indirect immunofluorescence (IIF) and reported a similar binding pattern [3436, 74]. The punctate staining seen with anti-mGluR1-positive sera was considered different from that reported for anti-Tr [35]. Outside the cerebellum, strong staining of neurons and neuropil was observed in the glomeruli of the olfactory bulb, the olfactory tubercle (including the islands of Calleja), the superficial layer of the cerebral cortex, the thalamus, the superior colliculus, the spinal trigeminal nucleus and the CA3 area [33] and dentate gyrus [34] of the hippocampus. See Fig. 3 for typical IHC findings.
Fig. 3

Binding of serum anti-mGluR1 from patients with ACA to rat (panels a and d) and mouse (panels b and c) cerebellum tissue sections. Patient antibodies were detected by use of goat anti-human IgG secondary antibodies labelled with Alexa Fluor®488 (panel a and d) or biotin (panel b: avidin/peroxidase; panel c: avidin/Texas red). While anti-mGluR1 strongly stain the molecular layer (a-d), staining of the PC somata varies in intensity depending on detection methods and antibody titres (compare panels a and c to panels b and d). Permission for panels b and c obtained from Massachusetts Medical Society. Copyright © (2000) Massachusetts Medical Society. Sillevis Smitt et al., Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000; 342:21-27

Antigen-specific assays

A cell-based assay (CBA) employing human embryonic kidney 293 (HEK293) cells transfected with human mGluR1a (Euroimmun, Luebeck, Germany) is available at the authors’ institution for use in scientific studies. Several other HEK293 or Chinese hamster ovary (CHO) in-house CBAs employing rat, mouse or human mGluR1 have been reported [3336]. The patient antibodies were shown to bind to isoform a in at least two studies (not specified in the remaining studies) [33, 34]. Other approaches to demonstrate specificity for mGluR1 included the use of cerebellum sections obtained from mGluR1-knockout mice, resulting in abolition of the typical staining pattern [33, 35], and an mGluR1 inhibition assay based on measurement of the glutamate-stimulated formation of inositol phosphates in CHO-transfected cells before and after incubation with patient serum [33].

CSF testing

The two index patients were positive for mGluR1 both in serum and in the CSF. However, titres per unit of IgG were 31 and 36 times as high in the CSF as in serum, indicating intrathecal synthesis [33]. In a third patient, a serum titre of 1:20,000 and a CSF titre of 1:500 were found in a fluorescence-based IHC assay [35]. CSF samples also tested positive in four studies of mGluR1-specific CBAs [3336].

Association with other autoantibodies

No association of anti-mGluR1 antibodies with other anti-neural antibodies (including anti-Hu, -Yo, -Ri, -Tr, -CV2/CRMP5, -Ma/Ta, -glutamic acid decarboxylase (GAD), -NMDAR, -AMPAR, -GABABR, -glycine receptors, leucine-rich, glioma inactivated 1 (LGI1), contactin-associated protein-2 (CASPR2), -amphiphysin, -Homer-3 and –Tr/DNER) has been found so far [3336]. Cross-reactivity with the structurally closely related mGluR5 receptor was excluded in three patients using HEK293- or CHO-based CBAs [33, 36].

Pathogenetic relevance

As a plasma membrane protein with a large extracellular domain [38, 39], mGluR1 is accessible to circulating IgG. Three independent studies consistently showed that anti-mGluR1 indeed targets the N-terminal, ligand-binding extracellular domain of native mGluR1a as indicated by their binding to living, i.e. unfixed, CHO or HEK cells expressing mGluR1 and by the lack of effect of anti-mGluR1 on PC function if injected intracellularly instead of being added extracellularly [33, 34, 75].

In contrast to most other antibodies discussed here, passive transfer experiments have been performed and strongly indicated a direct pathogenic effect of the antibody. Transfer of anti-mGluR1 into the subarachnoid space of normal mice, near the cerebellum, causes increasing ataxia with a wide and uncoordinated, irregular gait and a pathological rotorod test. The most strongly affected mice could hardly stand up owing to severe truncal ataxia [33]. Post-mortem analysis showed IgG deposits mainly in the cerebellum, including the cerebellar cortex [33]. The fact that antibodies eluted from mGluR1a-expressing CHO cells incubated with patient serum caused similar ataxic symptoms, while sera preadsorbed with such cells did not, proves that the effects were elicited by anti-mGluR1 and not by other antibodies potentially present in the patient serum [33].

As no freshly frozen human serum was co-injected as complement source and as the effect set in after a very short time and spontaneously subsided after 24 h, it is likely that ataxia was caused by functional blocking of mGluR1. Evidence for a functional impact of anti-mGluR1 on the receptor also comes from the demonstration of a dose-dependent decrease in glutamate-induced inositol phosphate formation following incubation of mGluR1a-expressing CHO cells with patient (but not control) IgG [33]. Similarly, IgG from anti-mGluR1-positive serum acutely reduced the holding inward current of PC in a slice culture model and markedly suppressed the inward current induced by (RS)-3,5-dihydroxyphenylglycine (DHPG), a selective agonist for group I mGluRs. The latter effect was reversible by a 20- to 40-min wash [75]. When incubated with spontaneously (unstimulated) firing PCs, a slight hyperpolarisation and thus hypoexcitability and a significant reduction in the action potential firing rate was noted [75]. Moreover, when applied in vivo directly to the flocculus of mice by a minipump, anti-mGluR1 (but not control IgG) strongly and acutely disturbed the visual component of compensatory eye movements as indicated by a reduction in the amplitude of the optokinetic reflex as well as the vestibulo–ocular reflex response in light; the effect was reversible by removal of the pump [75]. Finally, application of mGluR1 to cultured embryonic mouse PC during LTD induction strongly attenuated the LTD-defining decrease in the amplitude of the excitatory postsynaptic current following glutamate/depolarisation conjunctive stimulation at the PF/PC synapse [75]. While the calcium influx was unaltered, calcium mobilisation was significantly reduced, in line with the reduction in mGluR1-mediated inward current and the reduction of phosphatidylinositol turnover measured in mGluR1-expressing CHO cells [75].

Whether complement- or cell-mediated, antibody-related cytotoxicity is involved in the pathogenesis, in vivo has not been investigated thus far. Considering the prominent role of group I mGluRs in neuroprotection, blockade of the receptor might result in PC cell loss also in the absence of a strong immune reaction [7678]. Coesmans et al. [75] indeed found an (up to two third) decrease in the density of PCs in all parts of the cerebellar hemispheres and vermis in a post-mortem analysis of a patient, who had died from cardiac infarction. Of note, no signs of an ongoing inflammation (including cytotoxic CD8+ T lymphocytes previously reported in other types of ACA) were noted despite severe persisting ataxia at the time of death. In areas with PC loss, reactive Bergmann gliosis was present [75]. Moreover, PC morphology was affected with the dendritic trees of the remaining PCs being severely amputated [75]. In accordance with that finding, cerebellar atrophy indirectly indicating cell loss was detected by MRI in two further patients [34, 36].

Indirect evidence for a pathogenic role of the antibody comes from the demonstration of mGluR1-specific plasma cell clones within the CNS [33, 35] and from the fact that fading of ataxia after immunotherapy was paralleled by disappearance of the antibody [33]; by contrast, persistence of ataxia was accompanied by persisting serum and CSF anti-mGluR1 in a second patient [33].

Considering that only a subset of patients with mGluR1 reported so far had an accompanying tumour and that the receptor was not detectable in tumour samples renders a simple paraneoplastic aetiology caused to ectopic protein expression unlikely.

Molecular genetics

A pathogenic impact of anti-mGluR1 is also supported by molecular genetic findings linking mGluR1 dysfunction to cerebellar ataxia. Most importantly, autosomal recessive spinocerebellar ataxia-13 (SCA13) has been found to be caused by a complex homozygous mutation in the GRM1 gene encoding mGluR1 that results in aberrant transcripts lacking important functional domains [21]. SCA13 is a slowly progressive CNS disorder with onset in infancy that is characterised by moderate to severe gait, stance and limb ataxia with dysmetria, tremor, dysdiadochokinesia and dysarthria, and generalised cerebellar atrophy on MRI with small inferior vermis and retrocerebellar cysts, eye movement abnormalities (horizontal nystagmus, hypometric saccades, abduction deficits, esotropia, ptosis), mild to profound mental retardation with ventriculomegaly and/or generalised brain atrophy, poor or absent speech, and, in some, hyperreflexia and/or seizures [21].

Mutations in the mGluR1 gene cause cerebellar ataxia also in mice: A spontaneous mutation in the ligand-binding region of mGluR1 has been found to underlie ataxia in the recoil wobbler (rcw) strain of ataxic mouse [79]. Disruption of mGluR1 in mice by homologous recombination-mediated gene targeting was associated with atactic gait and intention tremor, although the gross anatomy of the cerebellum was widely normal, as was the excitatory synaptic transmission from PFs and CFs to PCs [46]. However, LTD (but not short-term synaptic plasticity) is clearly impaired in mGluR−/− mice [46], and multiple (instead of single) innervation of CFs to PCs was observed [46, 8082]. Similarly, no basic anatomical abnormalities were found in the hippocampus in mGluR1-deficient mice [45]; in contrast to the cerebellum, LTD was intact, but (mossy fibre) LTP and learning were impaired [45, 80, 83]. In rescue mice, all effects could be reversed in a dose-dependent manner by reconstitution of mGluR1 signalling [84].

Testing for spinocerebellar ataxia (SCA; types 1, 2, 3, 6, 7 and 17), Friedreich’s ataxia (FRDA), and fragile-X tremor-ataxia syndrome (FXTAS) has been carried out in one patient with mGluR1 antibodies and was negative [36].

Anti-Homer-3

Clinical, paraclinical and epidemiological features

The index patient (65/F) presented with vertigo, vomiting, dysarthria and severe subacute limb and gait ataxia. Ataxia was irreversible [85]. A second patient (38/M) also presented with nausea, vomiting and a pancerebellar syndrome but, in addition, developed signs of encephalitis including drowsiness, confusion and complex partial seizures. In this patient, elevated opening pressure and papilloedema was noted [86]. CSF analysis revealed lymphocytic pleocytosis in both cases (29 and 60 cells/μl); signs of intrathecal IgG synthesis were present in one patient. Brain MRI was normal at first examination in both patients, with no available follow-up in patient 1 and mild atrophy of the vermis and cerebellar hemispheres in patient 2 after 10 months. Onset of disease was subacute in both cases. Two additional (as yet unpublished) cases of ACA and Homer-3 antibodies have recently been diagnosed by us. No evidence has been found for a role of anti-Homer-3 in patients with chronic cerebellar ataxia (n = 27), patients with opsoclonus–myoclonus syndrome (n = 20) or healthy subjects (n = 20) [85, 86].

Association with tumours

Repeat tumour screening was negative in both published patients, with a follow-up period of 6 years in patient 1. One of the two as yet unpublished patients diagnosed at our laboratory had lung cancer (no data in the second), but no more detailed information is available.

Outcome and prognosis

While patient 1 did not respond to steroids, partial improvement was noted in patient 2 following treatment with IVIG and steroids. At last follow-up (72 and 24 months, respectively), patient 1 had severe ataxia, but patient 2 was still able to walk without help and carry out basic daily activities independently. It has been speculated that the suboptimal treatment response in patient 1 was due to the fact that significant Purkinje cell loss may occur very early in the clinical course, as seen in other antibody-mediated forms of ACA such as anti-Yo syndrome [86].

Antigen

Homer-3 is a constitutively expressed member of the Homer family of postsynaptic density (PSD) scaffolding proteins, which are characterised by enabled/vasodilator-stimulated phosphoprotein homology 1 (EVH1) domains. The EVH1 domain binds ligands on other proteins, including group I mGluRs, IP3 receptors, ryanodine receptors and Shank proteins. Homer-3 is thought to cross-link the cytoplasmic C-terminus of mGluR1 (especially the mGluR1a isoform [42, 43]) to ITPR1, both of which contain a proline-rich ‘Homer ligand’ (PPXXFR) [42]. Five isoforms of Homer-3 produced by alternative splicing are known to date in human. Besides Homer-3, two other Homer proteins with several isoforms have been described [42, 44, 8790]. The various Homer proteins and isoforms are thought to modify differentially synaptic mGluR properties including mGluR1 clustering, mGluR1-ITPR linkage and, functionally, the capability of mGluRs to trigger calcium responses [4244, 91, 92]. Ango et al. [41] suggested that Homer-3 prevents the so-called agonist (glutamate)-independent, constitutive activity specifically observed with isoform a of the mGluR1 receptor [93]. In the cerebellum, Homer-3 co-immunoprecipitates with structurally highly related Homer-1b [94], which influences translocation of the mGluRs from the ER to the plasma membrane, as well as with mGluR1 and ITPR1 [42]. Homer-3 may be regulated to some extent by the immediate-early gene product Homer-1a, its direct competitor on mGluR1a, which disrupts its binding to that receptor [41]. The coupling function of Homer-3 and thus the postsynaptic molecular architecture in response to synaptic activity in PCs has been proposed to be regulated by calcium/calmodulin-dependent protein kinase II (CaMKII)-mediated phosphorylation [95]. While non-phosphorylated Homer-3 is found mainly in the PSD, phosphorylated Homer-3 was found mainly in the cytosolic fraction [95]. Together with Shank, the Homer proteins form a mesh-like matrix structure that has been proposed to serve as a structural framework and as an assembly platform for other PSD proteins [9699]. A coiled-coil domain near the C-terminus allows formation of multimeric structures within the Homer family, and tetramerised Homer proteins are assumed to be required for structural integrity of the dendritic spines and recruitment of proteins to synapses [96].

Immunohistochemistry

Homer-3 is expressed at high level in PCs, where it is enriched in the dendritic spines, more precisely in the PSD of the PC/PF synapses (Fig. 4). However, it is also present in the somata and has been found in PC axons [89]. At lower levels, Homer-3 is expressed also in the cortex and hippocampus. In the latter, it is predominantly localised in the CA2 and CA3 regions (in contrast to Homer 1 and 2, which are more strongly expressed in the CA1 and CA2 regions) [89]. Outside the CNS, Homer-3 has been detected in thymus and lung. Using conventional biotin-avidin IHC on paraformaldehyde-fixed rat and human cerebellum tissue sections, binding of IgG from anti-Homer-3-positive sera to the molecular layer and, less intensely, the PC cytoplasm (but no other brain regions) has been found [85, 86]. Anti-Homer-3 autoantibodies are also detectable by IIF on unfixed or formalin-fixed frozen sections of mouse, rat or primate cerebellum tissue (Fig. 5).
Fig. 4

Expression of Homer-3 in the human cerebellum as demonstrated by IHC (modified image from the Human Protein Atlas image database [101]). Note that the main panel and the inset show different sectional planes

Fig. 5

Binding of anti-Homer-3 antibody from a patient with ACA to a mouse cerebellum tissue section. The patient antibody was detected by use of a goat anti-human IgG secondary antibody labelled with Alexa Fluor®488 (green)

Antigen-specific assays

Currently, a CBA employing HEK293 transfected with human Homer-3 (Euroimmun), a mixed phage display assay [85], Western blot assays using cerebellum sections from primate [74], rat, wild-type (47 kDa) and Homer-3-deficient mice [85] and an immunoblot assay employing a glutathione S-transferase-tagged Homer-3 [86] are available for use in scientific studies. A competitive inhibition IHC assay has been used to distinguish Homer-3 from mGluR1 [85].

CSF testing

CSF was not analysed for anti-Homer-3 in the only two patients whose cases have been published thus far.

Association with other autoantibodies

Anti-Homer-3 autoantibodies were not found in 32 sera from patients with other antibody-associated CNS disorders (14× anti-Tr, 17× anti-GAD, 1× anti-mGluR1). Conversely, anti-Homer-3-positive patients were reported to be negative for anti-Hu, -Yo, -Ri, -Ma1/2, -CV2/CRMP5, -Tr, -GAD, -amphiphysin and/or -NMDAR, -AMPAR, -GABABR, -mGluR1, -mGluR5, -LGI1 and -CASPR2.

Pathogenetic relevance

While the intracellular location of Homer-3 renders antibody-dependent cell- or complement-mediated cytotoxicity unlikely, the broad spectrum of functions and interactions of Homer-3 within PCs makes a functional impact of incorporated anti-Homer-3 IgG at least conceivable. Among other effects, blocking the interaction of Homer-3 with mGluR1a in PC could increase constitutive mGluR1 activity, as indicated by spontaneous inositol phosphate formation and spontaneous activity of calcium-dependent big K+ channel activity following Homer-3 knock-down in a cell culture model [41]. Passive transfer experiments that alone could prove a pathogenic effect of anti-Homer-3 are lacking so far.

Molecular genetics

To date, no mutations in the HOMER3 gene have been described in patients with SCA or other diseases.

Anti-Sj/ITPR1

Clinical, paraclinical and epidemiological features

Anti-ITPR1 (also termed anti-Sj) autoantibodies were first identified in 2010 and reported in 2014 [100]. So far, only four patients with anti-Sj/ITPR1 have been published, all of whom had cerebellar ataxia; however, we have identified another eight (as yet unpublished) cases in the meantime. Detailed clinical data are available only from a single case, a 28-year-old woman with a 10-year history of progressive ataxia of the upper limbs, dysarthria and gaze disturbances. MRI showed moderate cerebellar atrophy.

Association with tumours

The only patient with available data tested positive for a BRCA1 (breast cancer 1, early onset) gene mutation, which is associated with increased risk of cancer, but extensive tumour screening was negative. ITPR1 expression has been observed in breast cancer, liver cancer, lung cancer, melanoma, and lymphoma tissue by IHC as well as in a number of tumour cell lines [101].

Outcome and prognosis

The disease did not respond to steroids and ten cycles of PEX, but progression spontaneously came to a halt 3 years later. At last follow-up (9 years after onset), the patient was still able to work full-time in an office.

Antigen

ITPR1 (also termed IP3RI) is a ligand-gated non-selective cationic channel with sequence and functional homology with the ryanodine receptor. It is specifically gated by inositol 1,4,5-trisphosphate (IP3), a second messenger produced by phospholipase C through a G protein-dependent mechanism. ITPR1 is enriched in PCs (Fig. 6) [102104], where it is expressed mainly in the smooth ER membrane (and to a lesser degree on rough ER and nuclear envelope). Being involved in postsynaptic calcium responses by triggering Ca2+ release from the smooth ER as the main intracellular Ca2+ store following stimulation of mGluR1, to which it is physically coupled by Homer-3, ITPR1 plays an essential role in PC function.
Fig. 6

Expression of ITPR1 in the human cerebellum as demonstrated by IHC using an affinity-isolated rabbit antibody to human ITPR1 (Atlas antibodies, HPA016487). Modified image from the Human Protein Atlas image database [101]

To date, eight isoforms of ITPR1 produced by alternative splicing have been described [105]. Besides its IP3-binding domain, which is located near the N-terminus, ITPR1 contains a transmembrane spanning domain near the C-terminus, a coupling domain in the middle of the molecule, at least two consensus protein kinase A phosphorylation sites and at least one consensus ATP-binding site [105]. Among the many proteins suggested to interact with ITPR1, CARP VIII and IP3R-binding protein released with IP3 (IRBIT) regulate its IP3 sensitivity [2, 106].

Of note, ITPR1-mediated release of Ca2+ from the ER also plays an important role in the induction of apoptosis [107109]. Accordingly, inhibition or loss of inositol trisphosphate receptors [110112] as well as mutation in the N-terminal suppressor/coupling domain of ITPR1 have been shown to suppress apoptosis [113].

Immunohistochemistry

When tested by indirect immunofluorescence using snap-frozen cerebellum sections, anti-Sj/ITPR1 antibodies selectively bound to the entire dendritic tree in the cerebellar molecular layer including the dendritic spines [100, 102, 103] (Fig. 7), to the PC somata in the cerebellar PC layer, to the PC axons in the granular layer and the white matter and to the axonal terminals in the deep cerebellar nuclei. By contrast, granular cells, interneurons in the molecular layer and in the granular layer, the Bergman glial cells in the PC layer and the astrocytic and oligodendrocytic glial cells of the granular layer are spared. Anti-Sj/ITPR1 causes markedly stronger staining of the PC somata (somata ≥ dendrites) than anti-Ca/ARHGAP26 (somata < dendrites). In our experience, mouse and rat tissues seem to be more sensitive than primate tissue.
Fig. 7

Binding of IgG from a patient with ITPR1-Ab-positive ACA as determined in a recombinant cell-based assay to formalin-fixed rat cerebellum tissue. Human IgG was detected using a goat anti-human IgG secondary antibody labelled with Alexa Fluor®488 (green fluorescence)

ITPR1 has also been detected in neurons in the CA1 region of the hippocampus, in the caudate nucleus and putamen, in the cerebral cortex [114], in the presynaptic terminals of photoreceptor and bipolar cells [115] and in the plasma membrane of the olfactory cilia [116118]. High-titre samples may bind to smooth muscles on enteric tissue sections but spare the plexus myentericus.

Double-labelling experiments with a commercial antibody to ITPR1 can be employed to verify the presence of anti-Sj/ITPR1 antibodies when suspected (see [100] for an example).

Antigen-specific assays

A CBA employing HEK293 cells transfected with recombinant mouse ITPR1 and a dot–blot assay employing rat ITPR1 purified from brain tissue are available at the authors’ institution [100]. Specific neutralisation of the IHC reaction by preadsorption of patient sera with purified native rat ITPR1 has been used to confirm the presence of anti-ITPR1 [100].

CSF testing

Anti-Sj/ITPR1 has been identified from serum samples. Whether ITPR1 enters the CNS exclusively from the periphery or is also produced intrathecally is currently unknown. So far, testing of serum samples is recommended. However, given that many autoantibodies in neurological disease are produced intrathecally [119122] and that some are occasionally detectable only in the CSF [123], testing of CSF samples could potentially be useful in serum-negative cases.

Association with other antibodies

In the patients reported thus far, no association has been found with anti-Ca/ARHGAP26, anti-Hu, anti-Ri, anti-Yo, anti-Ma, anti-Ta, anti-CV2/CRMP5, anti-amphiphysin, ANNA-3, PCA-2, or anti-Tr/DNER, anti-Homer-3, anti-mGluR1, anti-CARP VIII, anti-AQP4, anti-myelin oligodendrocyte glycoprotein, anti-NMDA receptor, anti-AMPA receptors 1 and 2, anti-GABABR, anti-dipeptidyl-peptidase 6 (DPPX), anti-LGI1, anti-CASPR2, anti-PKCγ, anti-Zic4, anti-GAD, anti-amphiphysin or anti-GluRδ2 [100].

Pathogenetic relevance

As passive transfer experiments using IgG from anti-ITPR1-positive patients have not yet been performed, no direct evidence for a pathogenic impact of the antibody is currently available. Indirect evidence suggesting a potential pathogenic role of anti-ITPR1 include its high specificity for PCs and the association of ITPR1 defects with SCA, together with the fact that it mainly belongs to the IgG1 subclass [100] and is usually present at high titres [100]. On the other hand, ITPR1 is primarily an intracellular antigen and may not be accessible to antibodies in vivo. It is therefore possible that the antibody has diagnostic but no pathogenic impact, similar to the situation in many paraneoplastic neurological syndromes. However, surface localisation has also been reported under certain circumstances [124128], warranting further investigation.

Molecular genetics

Mutations in the ITPR1 gene have been implicated in both SCA15 and SCA29. SCA15, which has to be shown to be identical to SCA16 [129], is an autosomal dominant, very slowly progressive form of cerebellar ataxia with adult onset. In addition to ataxia, action and postural tremor, pyramidal tract and dorsal column involvement and gaze palsy have been noted. MRI revealed cerebellar atrophy, predominantly affecting the vermis [130]. In most affected families, large exon deletions have been found to underlie the disorder [25, 129131]. Accordingly, diagnosis is based on gene dosage studies rather than direct gene sequencing in such cases [25]. In Japanese patients, deletions involving the entire ITPR1 gene [132] and a heterozygous 8581C-T transition in exon 25 of the ITPR1 gene, resulting in a P1059L substitution in the ITPR1 gene [132], were identified.

SCA29 is an autosomal dominant disorder characterised by gait and limb ataxia with childhood onset and delayed motor and cognitive development. MRI shows cerebellar atrophy [133]. Two different heterozygous mutations in the ITPR1 gene, a 4657G-A transition resulting in a val1553-to-met (V1553M) substitution and a heterozygous 1804G-A transition in the ITPR1 gene resulting in an asn602-to-asp (N602D) substitution, respectively, have recently been found to underlie SCA29 in two affected families [133].

Anti-CARP VIII

Clinical, paraclinical and epidemiological features

So far, two patients with ACA and anti-CARP VIII have been reported. The index patient was a 77-year-old woman who presented with vertigo, severe limb and gait ataxia, dysarthria and horizontal nystagmus; symptoms developed within just 1 week [134]. In a second patient, a 69-year-old woman, intention tremor of the upper extremities, gait ataxia, cerebellar dysarthria and vertical nystagmus developed within 2 weeks; further symptoms included headache, vertigo and vomiting [135]. While brain MRI was normal in patient 1, repeat MRI showed progressive cerebellar atrophy 6 months later in patient 2. Lumbar puncture revealed a predominantly lymphocytic pleocytosis in both patients (60 and 290 cells/μl, respectively); CSF-restricted oligoclonal bands (OCB) were positive in the first patient and were not tested in the second patient.

Association with tumours

The index patient had been diagnosed with a nodular recurrence of malignant melanoma around 3 months before onset of cerebellar ataxia [134]. This is the first reported case of melanoma-associated paraneoplastic cerebellar degeneration (PCD). While the patient’s tumour was not examined for CARP VIII expression, the protein was shown to be expressed rarely in frozen sections of malignant melanomas from other patients [101, 134]. Anti-CARP VIII autoantibodies were not found in any of 52 patients with melanoma but no paraneoplastic syndromes [134]. The second patient was diagnosed with nodular recurrence of an ovarian papillary serous cystadenocarcinoma that had been resected and treated with chemotherapy 4 years prior to onset of ataxia. IHC of biopsy material from that patient revealed robust expression of CARP VIII in the tumour cells [135]. Besides in melanoma and ovarian carcinoma cells, expression of the normally neuron-restricted CARP VIII has also been found in colorectal and non-small-cell lung cancer cells [101].

Outcome and prognosis

The index patient developed a pancerebellar syndrome despite treatment with IVIG and died 1 year after onset of ataxia [134]. The clinical evolution was also unfavourable in the second patient, who became wheelchair-bound and developed severe dysarthria despite tumour removal and IVIG therapy [135].

Antigen

CARP VIII (also termed carbonic anhydrase VIII; encoded by CA8) belongs to an 11-member family of zinc metalloenzymes. While it shows sequence identity to other members of the cerebellar ataxia gene family and has a central CA motif, it lacks CA activity due to the absence of zinc-binding histidine residues [136, 137]. CARP VIII has been shown to reduce the affinity of ITPR1 for IP3 by its binding to the modulatory domain (residues 1387 to 1647) of that receptor via its residues 45 to 291 [2]. CARP VIII is predominantly expressed in PCs (Fig. 8) [2, 101] and is believed to have an important function in the development and maturation of these cells [138, 139].
Fig. 8

Expression of CARP VIII in the human cerebellum as demonstrated by IHC (modified image from the Human Protein Atlas image database [101])

Immunohistochemistry

In PCs, CARP VIII colocalises with ITPR1 [2], resulting in a similar IHC pattern in the two diseases (Fig. 9). CARP VIII immunoreactivity is highest in PCs of the cerebellum [2], with lower levels of expression in other areas of the brain, including the olfactory bulb, the lateral nuclei of the thalamus and a few isolated small neurons throughout the cortex and hippocampus [134, 140, 141]. Anti-CARP VIII has been shown to stain intensely the cytoplasm of the PC somata, the PC dendritic tree and the PC axons both in rat and human cerebellum [134], as well as the synaptic terminals in the deep cerebellar nuclei [135]. Outside the CNS, CARP VIII has been found in the lung, liver, adrenal glands and, weakly, in the bronchial epithelial cells and some tubules in the kidney cortex [134, 140, 141]. Of note, CARP VIII antibodies were detectable by IHC using avidin-biotin immunoperoxidase staining of frozen sections of paraformaldehyde-fixed rat tissues or of sections of snap-frozen acetone-fixed human tissues; by contrast, paraffin fixation abolished the staining [134].
Fig. 9

Binding of IgG from a patient with CARP VIII-Ab-positive ACA (as determined using a recombinant cell-based assay) to formalin-fixed rat cerebellum tissue. Human IgG was detected using a goat anti-human IgG secondary antibody labelled with fluorescein isothiocyanate (green fluorescence)

Antigen-specific assays

A CBA using HEK293 cells transfected with human CARP VIII (Euroimmun) is available at the authors’ institution for use in scientific studies. The antibody was first identified by screening a cerebellar complementary DNA (cDNA) expression library with the patient’s serum, subcloning, purification and sequencing of positive plaques. Filters with the purified phage plaques were subsequently used for detecting anti-CARP VIII in a second patient [135]. Fusion proteins produced by subcloned positive colonies were used for establishing a Western blot (WB) assay and an IHC preadsorption assay [134]. The protein was also shown to be reactive with a 29-kDa band in rat and human cerebellum extract [134, 135]. Finally, a competitive IHC inhibition assay using patient serum and subsequently biotinylated anti-CARP VIII IgG obtained from the index patient has been reported [135]; however, the latter type of assay requires, as a limitation, concordance in epitope specificity between patients.

CSF testing

In the index patient, anti-CARP VIII autoantibodies were present at high titres both in serum (1:160,000) and in the CSF (1:10,000). The high CSF levels indicated possible intrathecal synthesis [134]. CSF was not analysed for CARP VIII in the second patient.

Association with other autoantibodies

In the two patients reported thus far, no concomitant anti-Hu, -Yo, -Ri, -Ma1, -Ma2, -CV2/CRMP5, -sex-determining region Y-box (SOX) 1, -Tr, -glutamic acid decarboxylase, -amphiphysin, -VGCC, -LGI1, -CASPR2, -NMDAR, -AMPAR, -GABABR, -DPPX, -mGluR1, -mGluR5, or -glycine receptor antibodies were detected.

Pathogenetic relevance

Although anti-CARP VIII autoantibodies were present at extremely high titres in patient 1 and were shown to belong to the IgG1 subclass in patient 2, a direct pathogenic role of the antibody is unlikely given the intracellular location of CARP VIII. However, results from passive transfer experiments are lacking thus far.

Molecular genetics

Mutations in the CA8 gene have been found to be associated with congenital cerebellar ataxia and mild mental retardation with or without quadrupedal locomotion 3 [142, 143]. In mice, a deletion in exon 8 of the Car8 gene has been found in both the autosomal recessive ataxic and dystonic ‘waddles’ (wdl) mouse [144] and the autosomal recessive ataxic ‘Rigoletto’ (rig) mutant mouse [145]. Mutant mice show a largely diminished spontaneous PF/PC excitatory transmission with fewer functional synapses, PC spines not forming synapses and abnormal PC spines contacting multiple synaptic varicosities [145]. Absence of CARP VIII messenger RNA (mRNA) has been noted also in the atactic ‘lurcher’ mutant mouse [146]. In wdl mice, Car8 mutations did not influence ITPR1 expression [144].

Note to the reader

In Part 2 of this series, we will review the current knowledge on anti-PKCγ-, anti-GluRδ2-, anti-Ca/ARHGAP26- and anti-VGCC antibody-associated ACA [212]. In Part 3, we will focus on anti-Tr/DNER-,anti-Nb/AP3B2-, anti-Yo/CDR2- and PCA-2-associated ACA, discuss diagnostic pitfalls and provide a summary and outlook [213].

Abbreviations

Aa: 

amino acids

ACA: 

autoimmune cerebellar ataxia

AChR: 

acetylcholine receptor

ADEM: 

acute disseminated encephalomyelitis

AF: 

Alexa Fluor®

AGNA: 

anti-glial cell nuclear antibodies

AMPA: 

α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

ANA: 

anti-nuclear antibodies

ANNA: 

anti-neuronal nuclear antibody

APTX: 

aprataxin

AQP4: 

aquaporin-4

ARHGAP26: 

Rho GTPase-activating protein 26

ATXN1: 

ataxin-1

BAR: 

bin–amphiphysin–Rvs

beta-NAP: 

neuronal adaptin-like protein

CARP VIII: 

carbonic anhydrase-related protein VIII

CASPR2: 

contactin-associated protein-2

CBA: 

cell-based assay

cDNA: 

complementary DNA

CDR2: 

cerebellar degeneration-related protein 2

CDR2L: 

CDR2-like

CDR3: 

cerebellar degeneration-related autoantigen-3

CF: 

climbing fibre

CHO: 

Chinese hamster ovary

CNS: 

central nervous system

CSF: 

cerebrospinal fluid

CTL: 

cytotoxic T lymphocytes

DAG: 

diacylglycerol

DAPI: 

4',6-diamidino-2-phenylindole

DNA: 

deoxyribonucleic acid

DNER: 

delta notch-like epidermal growth factor-related receptor

DPPX: 

dipeptidyl-peptidase 6

EA2: 

episodic ataxia type 2

EGF: 

epidermal growth factor

ELISA: 

enzyme-linked immunosorbent assay

ER: 

endoplasmic reticulum

FHM1: 

familial hemiplegic migraine 1

FITC: 

fluorescein isothiocyanate

GABA: 

γ-aminobutyric acid

GABABR: 

GABA type B receptor

GAD: 

glutamic acid decarboxylase

GAP: 

Rho GTPase-activating protein

GFAP: 

glial fibrillary acidic protein

GL: 

granular layer

GluR: 

ionotropic glutamate receptors

GluRδ2: 

glutamate receptor delta 2

GRAF1: 

GTPase regulator associated with focal adhesion kinase 1

HEK: 

human embryonic kidney

IB: 

immunoblot assay

ICC: 

immunocytochemistry

IIF: 

indirect immunofluorescence

IgA: 

immunoglobulin A

IgG: 

immunoglobulin G

IgM: 

immunoglobulin M

IHC: 

immunohistochemistry

IP: 

immunoprecipitation assay

IP3: 

inositol 1,4,5-trisphosphate

IRBIT: 

IP3 receptor-binding protein released with IP3

ITPR1: 

inositol 1,4,5-trisphosphate receptor, type 1

IVIG: 

intravenous immunoglobulins

IVMP: 

intravenous methylprednisolone

kDa: 

kilodalton

LEMS: 

Lambert–Eaton syndrome

LGI1: 

leucine-rich, glioma inactivated 1

LTD: 

long-term depression

LTP: 

long-term potentiation

mGluR1: 

metabotropic glutamate receptor 1

ML: 

molecular layer

MRI: 

magnetic resonance imaging

mRNA: 

messenger RNA

NMDA: 

N-methyl D-aspartate

NMO: 

neuromyelitis optica

NSCLC: 

non-small cell lung cancer

NSE: 

neuron-specific enolase

OCB: 

oligoclonal bands

PC: 

Purkinje cell

PCA: 

Purkinje cell antibody

PCD: 

paraneoplastic cerebellar degeneration

PCL: 

PC layer

PF: 

parallel fibre

PIP2

phosphatidyl 4,5-bisphosphate

PKCγ: 

protein kinase C gamma

PLCβ3: 

phospholipase Cβ3

PSD: 

postsynaptic density

RACK: 

receptors for activated C kinases

RhoA: 

ras homolog gene family, member A

RIA: 

radioimmunoprecipitation assay

RNA: 

ribonucleic acid

SCA: 

spinocerebellar ataxia

SCLC: 

small cell lung cancer

SOX: 

sex-determining region Y-box

TRPC: 

canonical transient receptor potential channel

TUNEL: 

TdT-mediated dUTP-biotin nick end labelling

VGCC: 

voltage-gated potassium channel

VGKC: 

voltage-gated potassium channel

WB: 

Western blot

WM: 

white matter

Declarations

Acknowledgements

The authors would like to thank Mrs Anna Eschlbeck and the Nikon Imaging Center at the University of Heidelberg for excellent technical assistance.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Molecular Neuroimmunology Group, Department of Neurology, University of Heidelberg, Otto Meyerhof Center

References

  1. Finch EA, Augustine GJ. Local calcium signalling by inositol-1,4,5-trisphosphate in Purkinje cell dendrites. Nature. 1998;396:753–6.PubMedView ArticleGoogle Scholar
  2. Hirota J, Ando H, Hamada K, Mikoshiba K. Carbonic anhydrase-related protein is a novel binding protein for inositol 1,4,5-trisphosphate receptor type 1. Biochem J. 2003;372:435–41.PubMed CentralPubMedView ArticleGoogle Scholar
  3. Bell RM. Protein kinase C activation by diacylglycerol second messengers. Cell. 1986;45:631–2.PubMedView ArticleGoogle Scholar
  4. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, Schultz G. Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature. 1999;397:259–63.PubMedView ArticleGoogle Scholar
  5. Hartmann J, Dragicevic E, Adelsberger H, Henning HA, Sumser M, Abramowitz J, et al. TRPC3 channels are required for synaptic transmission and motor coordination. Neuron. 2008;59:392–8.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Venkatachalam K, Zheng F, Gill DL. Regulation of canonical transient receptor potential (TRPC) channel function by diacylglycerol and protein kinase C. J Biol Chem. 2003;278:29031–40.PubMedView ArticleGoogle Scholar
  7. Adachi N, Kobayashi T, Takahashi H, Kawasaki T, Shirai Y, Ueyama T, et al. Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem. 2008;283:19854–63.PubMedView ArticleGoogle Scholar
  8. Kato AS, Knierman MD, Siuda ER, Isaac JT, Nisenbaum ES, Bredt DS. Glutamate receptor delta2 associates with metabotropic glutamate receptor 1 (mGluR1), protein kinase Cgamma, and canonical transient receptor potential 3 and regulates mGluR1-mediated synaptic transmission in cerebellar Purkinje neurons. J Neurosci. 2012;32:15296–308.PubMedView ArticleGoogle Scholar
  9. Trebak M, St JBG, McKay RR, Birnbaumer L, Putney Jr JW. Signaling mechanism for receptor-activated canonical transient receptor potential 3 (TRPC3) channels. J Biol Chem. 2003;278:16244–52.PubMedView ArticleGoogle Scholar
  10. Glitsch MD. Activation of native TRPC3 cation channels by phospholipase D. FASEB J. 2010;24:318–25.PubMedView ArticleGoogle Scholar
  11. Doherty AJ, Coutinho V, Collingridge GL, Henley JM. Rapid internalization and surface expression of a functional, fluorescently tagged G-protein-coupled glutamate receptor. Biochem J. 1999;341(Pt 2):415–22.PubMed CentralPubMedView ArticleGoogle Scholar
  12. Mundell SJ, Matharu AL, Pula G, Roberts PJ, Kelly E. Agonist-induced internalization of the metabotropic glutamate receptor 1a is arrestin- and dynamin-dependent. J Neurochem. 2001;78:546–51.PubMedView ArticleGoogle Scholar
  13. Graus F, Lang B, Pozo-Rosich P, Saiz A, Casamitjana R, Vincent A. P/Q type calcium-channel antibodies in paraneoplastic cerebellar degeneration with lung cancer. Neurology. 2002;59:764–6.PubMedView ArticleGoogle Scholar
  14. Burk K, Wick M, Roth G, Decker P, Voltz R. Antineuronal antibodies in sporadic late-onset cerebellar ataxia. J Neurol. 2010;257:59–62.PubMedView ArticleGoogle Scholar
  15. Schubert M, Panja D, Haugen M, Bramham CR, Vedeler CA. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis. Acta Neuropathol. 2014;128:835–52.PubMed CentralPubMedView ArticleGoogle Scholar
  16. Kitano J, Nishida M, Itsukaichi Y, Minami I, Ogawa M, Hirano T, et al. Direct interaction and functional coupling between metabotropic glutamate receptor subtype 1 and voltage-sensitive Cav2.1 Ca2+ channel. J Biol Chem. 2003;278:25101–8.PubMedView ArticleGoogle Scholar
  17. Beqollari D, Kammermeier PJ. The interaction between mGluR1 and the calcium channel Cav(2). (1) preserves coupling in the presence of long Homer proteins. Neuropharmacology. 2013;66:302–10.PubMed CentralPubMedView ArticleGoogle Scholar
  18. Ohtani Y, Miyata M, Hashimoto K, Tabata T, Kishimoto Y, Fukaya M, et al. The synaptic targeting of mGluR1 by its carboxyl-terminal domain is crucial for cerebellar function. J Neurosci. 2014;34:2702–12.PubMedView ArticleGoogle Scholar
  19. Choi S, Lovinger DM. Metabotropic glutamate receptor modulation of voltage-gated Ca2+ channels involves multiple receptor subtypes in cortical neurons. J Neurosci. 1996;16:36–45.PubMedGoogle Scholar
  20. Stefani A, Spadoni F, Bernardi G. Group I mGluRs modulate calcium currents in rat GP: functional implications. Synapse. 1998;30:424–32.PubMedView ArticleGoogle Scholar
  21. Guergueltcheva V, Azmanov DN, Angelicheva D, Smith KR, Chamova T, Florez L, et al. Autosomal-recessive congenital cerebellar ataxia is caused by mutations in metabotropic glutamate receptor 1. Am J Hum Genet. 2012;91:553–64.PubMed CentralPubMedView ArticleGoogle Scholar
  22. Offermanns S, Hashimoto K, Watanabe M, Sun W, Kurihara H, Thompson RF, et al. Impaired motor coordination and persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking Galphaq. Proc Natl Acad Sci U S A. 1997;94:14089–94.PubMed CentralPubMedView ArticleGoogle Scholar
  23. Hartmann J, Blum R, Kovalchuk Y, Adelsberger H, Kuner R, Durand GM, et al. Distinct roles of Galpha(q) and Galpha11 for Purkinje cell signaling and motor behavior. J Neurosci. 2004;24:5119–30.PubMedView ArticleGoogle Scholar
  24. Miyata M, Kim HT, Hashimoto K, Lee TK, Cho SY, Jiang H, et al. Deficient long-term synaptic depression in the rostral cerebellum correlated with impaired motor learning in phospholipase C beta4 mutant mice. Eur J Neurosci. 2001;13:1945–54.PubMedView ArticleGoogle Scholar
  25. van de Leemput J, Chandran J, Knight MA, Holtzclaw LA, Scholz S, Cookson MR, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet. 2007;3:e108.PubMed CentralPubMedView ArticleGoogle Scholar
  26. Chen DH, Brkanac Z, Verlinde CL, Tan XJ, Bylenok L, Nochlin D, et al. Missense mutations in the regulatory domain of PKC gamma: a new mechanism for dominant nonepisodic cerebellar ataxia. Am J Hum Genet. 2003;72:839–49.PubMed CentralPubMedView ArticleGoogle Scholar
  27. Skinner PJ, Vierra-Green CA, Clark HB, Zoghbi HY, Orr HT. Altered trafficking of membrane proteins in purkinje cells of SCA1 transgenic mice. Am J Pathol. 2001;159:905–13.PubMed CentralPubMedView ArticleGoogle Scholar
  28. Ikeda Y, Dick KA, Weatherspoon MR, Gincel D, Armbrust KR, Dalton JC, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet. 2006;38:184–90.PubMedView ArticleGoogle Scholar
  29. Maier A, Klopocki E, Horn D, Tzschach A, Holm T, Meyer R, et al. De novo partial deletion in GRID2 presenting with complicated spastic paraplegia. Muscle Nerve. 2014;49:289–92.PubMedView ArticleGoogle Scholar
  30. Zhuchenko O, Bailey J, Bonnen P, Ashizawa T, Stockton DW, Amos C, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet. 1997;15:62–9.PubMedView ArticleGoogle Scholar
  31. Ishikawa K, Tanaka H, Saito M, Ohkoshi N, Fujita T, Yoshizawa K, et al. Japanese families with autosomal dominant pure cerebellar ataxia map to chromosome 19p13.1-p13.2 and are strongly associated with mild CAG expansions in the spinocerebellar ataxia type 6 gene in chromosome 19p13.1. Am J Hum Genet. 1997;61:336–46.PubMed CentralPubMedView ArticleGoogle Scholar
  32. Kordasiewicz HB, Gomez CM. Molecular pathogenesis of spinocerebellar ataxia type 6. Neurotherapeutics. 2007;4:285–94.PubMedView ArticleGoogle Scholar
  33. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, et al. Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med. 2000;342:21–7.PubMedView ArticleGoogle Scholar
  34. Iorio R, Damato V, Mirabella M, Vita MG, Hulsenboom E, Plantone D, et al. Cerebellar degeneration associated with mGluR1 autoantibodies as a paraneoplastic manifestation of prostate adenocarcinoma. J Neuroimmunol. 2013;263:155–8.PubMedView ArticleGoogle Scholar
  35. Marignier R, Chenevier F, Rogemond V, Sillevis Smitt P, Renoux C, Cavillon G, et al. Metabotropic glutamate receptor type 1 autoantibody-associated cerebellitis: a primary autoimmune disease? Arch Neurol. 2010;67:627–30.PubMedView ArticleGoogle Scholar
  36. Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine JC, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698–701.PubMed CentralPubMedView ArticleGoogle Scholar
  37. Hermans E, Challiss RA. Structural, signalling and regulatory properties of the group I metabotropic glutamate receptors: prototypic family C G-protein-coupled receptors. Biochem J. 2001;359:465–84.PubMed CentralPubMedView ArticleGoogle Scholar
  38. Stephan D, Bon C, Holzwarth JA, Galvan M, Pruss RM. Human metabotropic glutamate receptor 1: mRNA distribution, chromosome localization and functional expression of two splice variants. Neuropharmacology. 1996;35:1649–60.PubMedView ArticleGoogle Scholar
  39. Makoff AJ, Phillips T, Pilling C, Emson P. Expression of a novel splice variant of human mGluR1 in the cerebellum. Neuroreport. 1997;8:2943–7.PubMedView ArticleGoogle Scholar
  40. Kammermeier PJ, Ikeda SR. Expression of RGS2 alters the coupling of metabotropic glutamate receptor 1a to M-type K+ and N-type Ca2+ channels. Neuron. 1999;22:819–29.PubMedView ArticleGoogle Scholar
  41. Ango F, Prezeau L, Muller T, Tu JC, Xiao B, Worley PF, et al. Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature. 2001;411:962–5.PubMedView ArticleGoogle Scholar
  42. Tu JC, Xiao B, Yuan JP, Lanahan AA, Leoffert K, Li M, et al. Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron. 1998;21:717–26.PubMedView ArticleGoogle Scholar
  43. Xiao B, Tu JC, Petralia RS, Yuan JP, Doan A, Breder CD, et al. Homer regulates the association of group 1 metabotropic glutamate receptors with multivalent complexes of homer-related, synaptic proteins. Neuron. 1998;21:707–16.PubMedView ArticleGoogle Scholar
  44. Brakeman PR, Lanahan AA, O’Brien R, Roche K, Barnes CA, Huganir RL, et al. Homer: a protein that selectively binds metabotropic glutamate receptors. Nature. 1997;386:284–8.PubMedView ArticleGoogle Scholar
  45. Aiba A, Chen C, Herrup K, Rosenmund C, Stevens CF, Tonegawa S. Reduced hippocampal long-term potentiation and context-specific deficit in associative learning in mGluR1 mutant mice. Cell. 1994;79:365–75.PubMedView ArticleGoogle Scholar
  46. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, et al. Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell. 1994;79:377–88.PubMedView ArticleGoogle Scholar
  47. Anwyl R. Metabotropic glutamate receptor-dependent long-term potentiation. Neuropharmacology. 2009;56:735–40.PubMedView ArticleGoogle Scholar
  48. Kim SJ, Kim YS, Yuan JP, Petralia RS, Worley PF, Linden DJ. Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluR1. Nature. 2003;426:285–91.PubMedView ArticleGoogle Scholar
  49. Tabata T, Araishi K, Hashimoto K, Hashimotodani Y, van der Putten H, Bettler B, et al. Ca2+ activity at GABAB receptors constitutively promotes metabotropic glutamate signaling in the absence of GABA. Proc Natl Acad Sci U S A. 2004;101:16952–7.PubMed CentralPubMedView ArticleGoogle Scholar
  50. Jarius S, Steinmeyer F, Knobel A, Streitberger K, Hotter B, Horn S, et al. GABAB receptor antibodies in paraneoplastic cerebellar ataxia. J Neuroimmunol. 2013;256:94–6.PubMedView ArticleGoogle Scholar
  51. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, et al. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–76.PubMed CentralPubMedView ArticleGoogle Scholar
  52. Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology. 2011;76:795–800.PubMed CentralPubMedView ArticleGoogle Scholar
  53. Skeberdis VA, Lan J, Opitz T, Zheng X, Bennett MV, Zukin RS. mGluR1-mediated potentiation of NMDA receptors involves a rise in intracellular calcium and activation of protein kinase C. Neuropharmacology. 2001;40:856–65.PubMedView ArticleGoogle Scholar
  54. Calo L, Bruno V, Spinsanti P, Molinari G, Korkhov V, Esposito Z, et al. Interactions between ephrin-B and metabotropic glutamate 1 receptors in brain tissue and cultured neurons. J Neurosci. 2005;25:2245–54.PubMedView ArticleGoogle Scholar
  55. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–8.PubMed CentralPubMedView ArticleGoogle Scholar
  56. Ciruela F, Escriche M, Burgueno J, Angulo E, Casado V, Soloviev MM, et al. Metabotropic glutamate 1alpha and adenosine A1 receptors assemble into functionally interacting complexes. J Biol Chem 2001;276:18345-18351.Google Scholar
  57. Shipley MT, Ennis M. Functional organization of olfactory system. J Neurobiol. 1996;30:123–76.PubMedView ArticleGoogle Scholar
  58. Baude A, Nusser Z, Roberts JD, Mulvihill E, McIlhinney RA, Somogyi P. The metabotropic glutamate receptor (mGluR1 alpha) is concentrated at perisynaptic membrane of neuronal subpopulations as detected by immunogold reaction. Neuron. 1993;11:771–87.PubMedView ArticleGoogle Scholar
  59. Ebling FJ. The role of glutamate in the photic regulation of the suprachiasmatic nucleus. Prog Neurobiol. 1996;50:109–32.PubMedView ArticleGoogle Scholar
  60. Johnson MP, Kelly G, Chamberlain M. Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists. J Neuroendocrinol. 2001;13:670–7.PubMedView ArticleGoogle Scholar
  61. Vidnyanszky Z, Gorcs TJ, Negyessy L, Borostyankio Z, Knopfel T, Hamori J. Immunocytochemical visualization of the mGluR1a metabotropic glutamate receptor at synapses of corticothalamic terminals originating from area 17 of the rat. Eur J Neurosci. 1996;8:1061–71.PubMedView ArticleGoogle Scholar
  62. Turner JP, Salt TE. Synaptic activation of the group I metabotropic glutamate receptor mGlu1 on the thalamocortical neurons of the rat dorsal lateral geniculate nucleus in vitro. Neuroscience. 2000;100:493–505.PubMedView ArticleGoogle Scholar
  63. Neugebauer V, Chen PS, Willis WD. Role of metabotropic glutamate receptor subtype mGluR1 in brief nociception and central sensitization of primate STT cells. J Neurophysiol. 1999;82:272–82.PubMedGoogle Scholar
  64. Neugebauer V. Metabotropic glutamate receptors—important modulators of nociception and pain behavior. Pain. 2002;98:1–8.PubMedView ArticleGoogle Scholar
  65. Martin LJ, Blackstone CD, Huganir RL, Price DL. Cellular localization of a metabotropic glutamate receptor in rat brain. Neuron. 1992;9:259–70.PubMedView ArticleGoogle Scholar
  66. Shigemoto R, Nakanishi S, Mizuno N. Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol. 1992;322:121–35.PubMedView ArticleGoogle Scholar
  67. Russo RE, Nagy F, Hounsgaard J. Modulation of plateau properties in dorsal horn neurones in a slice preparation of the turtle spinal cord. J Physiol. 1997;499(Pt 2):459–74.PubMed CentralPubMedView ArticleGoogle Scholar
  68. Berthele A, Boxall SJ, Urban A, Anneser JM, Zieglgansberger W, Urban L, et al. Distribution and developmental changes in metabotropic glutamate receptor messenger RNA expression in the rat lumbar spinal cord. Brain Res Dev Brain Res. 1999;112:39–53.PubMedView ArticleGoogle Scholar
  69. Zhong J, Gerber G, Kojic L, Randic M. Dual modulation of excitatory synaptic transmission by agonists at group I metabotropic glutamate receptors in the rat spinal dorsal horn. Brain Res. 2000;887:359–77.PubMedView ArticleGoogle Scholar
  70. Shigemoto R, Kinoshita A, Wada E, Nomura S, Ohishi H, Takada M, et al. Differential presynaptic localization of metabotropic glutamate receptor subtypes in the rat hippocampus. J Neurosci. 1997;17:7503–22.PubMedGoogle Scholar
  71. Mateos JM, Benitez R, Elezgarai I, Azkue JJ, Lazaro E, Osorio A, et al. Immunolocalization of the mGluR1b splice variant of the metabotropic glutamate receptor 1 at parallel fiber-Purkinje cell synapses in the rat cerebellar cortex. J Neurochem. 2000;74:1301–9.PubMedView ArticleGoogle Scholar
  72. Grandes P, Mateos JM, Ruegg D, Kuhn R, Knopfel T. Differential cellular localization of three splice variants of the mGluR1 metabotropic glutamate receptor in rat cerebellum. Neuroreport. 1994;5:2249–52.PubMedView ArticleGoogle Scholar
  73. Ango F, Albani-Torregrossa S, Joly C, Robbe D, Michel JM, Pin JP, et al. A simple method to transfer plasmid DNA into neuronal primary cultures: functional expression of the mGlu5 receptor in cerebellar granule cells. Neuropharmacology. 1999;38:793–803.PubMedView ArticleGoogle Scholar
  74. Jarius S, Wandinger KP, Horn S, Heuer H, Wildemann B. A new Purkinje cell antibody (anti-Ca) associated with subacute cerebellar ataxia: immunological characterization. J Neuroinflammation. 2010;7:21.PubMed CentralPubMedView ArticleGoogle Scholar
  75. Coesmans M, Smitt PA, Linden DJ, Shigemoto R, Hirano T, Yamakawa Y, et al. Mechanisms underlying cerebellar motor deficits due to mGluR1-autoantibodies. Ann Neurol. 2003;53:325–36.PubMedView ArticleGoogle Scholar
  76. Copani A, Bruno V, Battaglia G, Leanza G, Pellitteri R, Russo A, et al. Activation of metabotropic glutamate receptors protects cultured neurons against apoptosis induced by beta-amyloid peptide. Mol Pharmacol. 1995;47:890–7.PubMedGoogle Scholar
  77. Copani A, Bruno VM, Barresi V, Battaglia G, Condorelli DF, Nicoletti F. Activation of metabotropic glutamate receptors prevents neuronal apoptosis in culture. J Neurochem. 1995;64:101–8.PubMedView ArticleGoogle Scholar
  78. Maiese K, Vincent A, Lin SH, Shaw T: Group I and group III metabotropic glutamate receptor subtypes provide enhanced neuroprotection. J Neurosci Res 2000, 62:257–272.PubMedView ArticleGoogle Scholar
  79. Sachs AJ, Schwendinger JK, Yang AW, Haider NB, Nystuen AM. The mouse mutants recoil wobbler and nmf373 represent a series of Grm1 mutations. Mamm Genome. 2007;18:749–56.PubMedView ArticleGoogle Scholar
  80. Conquet F, Bashir ZI, Davies CH, Daniel H, Ferraguti F, Bordi F, et al. Motor deficit and impairment of synaptic plasticity in mice lacking mGluR1. Nature. 1994;372:237–43.PubMedView ArticleGoogle Scholar
  81. Kano M, Hashimoto K, Kurihara H, Watanabe M, Inoue Y, Aiba A, et al. Persistent multiple climbing fiber innervation of cerebellar Purkinje cells in mice lacking mGluR1. Neuron. 1997;18:71–9.PubMedView ArticleGoogle Scholar
  82. Levenes C, Daniel H, Jaillard D, Conquet F, Crepel F. Incomplete regression of multiple climbing fibre innervation of cerebellar Purkinje cells in mGLuR1 mutant mice. Neuroreport. 1997;8:571–4.PubMedView ArticleGoogle Scholar
  83. Gil-Sanz C, Delgado-Garcia JM, Fairen A, Gruart A. Involvement of the mGluR1 receptor in hippocampal synaptic plasticity and associative learning in behaving mice. Cereb Cortex. 2008;18:1653–63.PubMedView ArticleGoogle Scholar
  84. Ichise T, Kano M, Hashimoto K, Yanagihara D, Nakao K, Shigemoto R, et al. mGluR1 in cerebellar Purkinje cells essential for long-term depression, synapse elimination, and motor coordination. Science. 2000;288:1832–5.PubMedView ArticleGoogle Scholar
  85. Zuliani L, Sabater L, Saiz A, Baiges JJ, Giometto B, Graus F. Homer 3 autoimmunity in subacute idiopathic cerebellar ataxia. Neurology. 2007;68:239–40.PubMedView ArticleGoogle Scholar
  86. Hoftberger R, Sabater L, Ortega A, Dalmau J, Graus F. Patient with homer-3 antibodies and cerebellitis. JAMA Neurol. 2013;70:506–9.PubMed CentralPubMedView ArticleGoogle Scholar
  87. Kato A, Ozawa F, Saitoh Y, Fukazawa Y, Sugiyama H, Inokuchi K. Novel members of the Vesl/Homer family of PDZ proteins that bind metabotropic glutamate receptors. J Biol Chem. 1998;273:23969–75.PubMedView ArticleGoogle Scholar
  88. Sun J, Tadokoro S, Imanaka T, Murakami SD, Nakamura M, Kashiwada K, et al. Isolation of PSD-Zip45, a novel Homer/vesl family protein containing leucine zipper motifs, from rat brain. FEBS Lett. 1998;437:304–8.PubMedView ArticleGoogle Scholar
  89. Shiraishi-Yamaguchi Y, Furuichi T. The Homer family proteins. Genome Biol. 2007;8:206.PubMed CentralPubMedView ArticleGoogle Scholar
  90. Kato A, Ozawa F, Saitoh Y, Hirai K, Inokuchi K. vesl, a gene encoding VASP/Ena family related protein, is upregulated during seizure, long-term potentiation and synaptogenesis. FEBS Lett. 1997;412:183–9.PubMedView ArticleGoogle Scholar
  91. Kammermeier PJ. Surface clustering of metabotropic glutamate receptor 1 induced by long Homer proteins. BMC Neurosci. 2006;7:1.PubMed CentralPubMedView ArticleGoogle Scholar
  92. Kammermeier PJ, Xiao B, Tu JC, Worley PF, Ikeda SR. Homer proteins regulate coupling of group I metabotropic glutamate receptors to N-type calcium and M-type potassium channels. J Neurosci. 2000;20:7238–45.PubMedGoogle Scholar
  93. Prezeau L, Gomeza J, Ahern S, Mary S, Galvez T, Bockaert J, et al. Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol. 1996;49:422–9.PubMedGoogle Scholar
  94. Roche KW, Tu JC, Petralia RS, Xiao B, Wenthold RJ, Worley PF. Homer 1b regulates the trafficking of group I metabotropic glutamate receptors. J Biol Chem. 1999;274:25953–7.PubMedView ArticleGoogle Scholar
  95. Mizutani A, Kuroda Y, Futatsugi A, Furuichi T, Mikoshiba K. Phosphorylation of Homer3 by calcium/calmodulin-dependent kinase II regulates a coupling state of its target molecules in Purkinje cells. J Neurosci. 2008;28:5369–82.PubMedView ArticleGoogle Scholar
  96. Hayashi MK, Tang C, Verpelli C, Narayanan R, Stearns MH, Xu RM, et al. The postsynaptic density proteins Homer and Shank form a polymeric network structure. Cell. 2009;137:159–71.PubMed CentralPubMedView ArticleGoogle Scholar
  97. Kammermeier PJ, Worley PF. Homer 1a uncouples metabotropic glutamate receptor 5 from postsynaptic effectors. Proc Natl Acad Sci U S A. 2007;104:6055–60.PubMed CentralPubMedView ArticleGoogle Scholar
  98. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, et al. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron. 1999;23:583–92.PubMedView ArticleGoogle Scholar
  99. Sheng M. The postsynaptic NMDA-receptor—PSD-95 signaling complex in excitatory synapses of the brain. J Cell Sci. 2001;114:1251.PubMedGoogle Scholar
  100. Jarius S, Scharf M, Begemann N, Stocker W, Probst C, Serysheva II, et al. Antibodies to the inositol 1,4,5-trisphosphate receptor type 1 (ITPR1) in cerebellar ataxia. J Neuroinflammation. 2014;11:206.PubMed CentralPubMedView ArticleGoogle Scholar
  101. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015;347:1260419.PubMedView ArticleGoogle Scholar
  102. Otsu H, Yamamoto A, Maeda N, Mikoshiba K, Tashiro Y. Immunogold localization of inositol 1, 4, 5-trisphosphate (InsP3) receptor in mouse cerebellar Purkinje cells using three monoclonal antibodies. Cell Struct Funct. 1990;15:163–73.PubMedView ArticleGoogle Scholar
  103. Satoh T, Ross CA, Villa A, Supattapone S, Pozzan T, Snyder SH, et al. The inositol 1,4,5,-trisphosphate receptor in cerebellar Purkinje cells: quantitative immunogold labeling reveals concentration in an ER subcompartment. J Cell Biol. 1990;111:615–24.PubMedView ArticleGoogle Scholar
  104. Furuichi T, Simon-Chazottes D, Fujino I, Yamada N, Hasegawa M, Miyawaki A, et al. Widespread expression of inositol 1,4,5-trisphosphate receptor type 1 gene (Insp3r1) in the mouse central nervous system. Receptors Channels. 1993;1:11–24.PubMedGoogle Scholar
  105. Nucifora Jr FC, Li SH, Danoff S, Ullrich A, Ross CA. Molecular cloning of a cDNA for the human inositol 1,4,5-trisphosphate receptor type 1, and the identification of a third alternatively spliced variant. Brain Res Mol Brain Res. 1995;32:291–6.PubMedView ArticleGoogle Scholar
  106. Vanderheyden V, Devogelaere B, Missiaen L, De Smedt H, Bultynck G, Parys JB. Regulation of inositol 1,4,5-trisphosphate-induced Ca2+ release by reversible phosphorylation and dephosphorylation. Biochim Biophys Acta. 2009;1793:959–70.PubMed CentralPubMedView ArticleGoogle Scholar
  107. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003;4:552–65.PubMedView ArticleGoogle Scholar
  108. Boehning D, Patterson RL, Sedaghat L, Glebova NO, Kurosaki T, Snyder SH. Cytochrome c binds to inositol (1,4,5) trisphosphate receptors, amplifying calcium-dependent apoptosis. Nat Cell Biol. 2003;5:1051–61.PubMedView ArticleGoogle Scholar
  109. Boehning D, Patterson RL, Snyder SH. Apoptosis and calcium: new roles for cytochrome c and inositol 1,4,5-trisphosphate. Cell Cycle. 2004;3:252–4.PubMedView ArticleGoogle Scholar
  110. Akimzhanov AM, Barral JM, Boehning D. Caspase 3 cleavage of the inositol 1,4,5-trisphosphate receptor does not contribute to apoptotic calcium release. Cell Calcium. 2013;53:152–8.PubMed CentralPubMedView ArticleGoogle Scholar
  111. Jayaraman T, Marks AR. T cells deficient in inositol 1,4,5-trisphosphate receptor are resistant to apoptosis. Mol Cell Biol. 1997;17:3005–12.PubMed CentralPubMedView ArticleGoogle Scholar
  112. Boehning D, van Rossum DB, Patterson RL, Snyder SH. A peptide inhibitor of cytochrome c/inositol 1,4,5-trisphosphate receptor binding blocks intrinsic and extrinsic cell death pathways. Proc Natl Acad Sci U S A. 2005;102:1466–71.PubMed CentralPubMedView ArticleGoogle Scholar
  113. Szlufcik K, Bultynck G, Callewaert G, Missiaen L, Parys JB, De Smedt H. The suppressor domain of inositol 1,4,5-trisphosphate receptor plays an essential role in the protection against apoptosis. Cell Calcium. 2006;39:325–36.PubMedView ArticleGoogle Scholar
  114. Matsumoto M, Nakagawa T, Inoue T, Nagata E, Tanaka K, Takano H, et al. Ataxia and epileptic seizures in mice lacking type 1 inositol 1,4,5-trisphosphate receptor. Nature. 1996;379:168–71.PubMedView ArticleGoogle Scholar
  115. Peng YW, Sharp AH, Snyder SH, Yau KW. Localization of the inositol 1,4,5-trisphosphate receptor in synaptic terminals in the vertebrate retina. Neuron. 1991;6:525–31.PubMedView ArticleGoogle Scholar
  116. Fadool DA, Ache BW. Plasma membrane inositol 1,4,5-trisphosphate-activated channels mediate signal transduction in lobster olfactory receptor neurons. Neuron. 1992;9:907–18.PubMed CentralPubMedView ArticleGoogle Scholar
  117. Restrepo D, Teeter JH, Honda E, Boyle AG, Marecek JF, Prestwich GD, et al. Evidence for an InsP3-gated channel protein in isolated rat olfactory cilia. Am J Physiol. 1992;263:C667–73.PubMedGoogle Scholar
  118. Cunningham AM, Ryugo DK, Sharp AH, Reed RR, Snyder SH, Ronnett GV. Neuronal inositol 1,4,5-trisphosphate receptor localized to the plasma membrane of olfactory cilia. Neuroscience. 1993;57:339–52.PubMedView ArticleGoogle Scholar
  119. Jarius S, Stich O, Speck J, Rasiah C, Wildemann B, Meinck HM, et al. Qualitative and quantitative evidence of anti-glutamic acid decarboxylase-specific intrathecal antibody synthesis in patients with stiff person syndrome. J Neuroimmunol. 2010;229:219–24.PubMedView ArticleGoogle Scholar
  120. Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol. 2007;183:220–4.PubMedView ArticleGoogle Scholar
  121. Jarius S, Stich O, Rasiah C, Voltz R, Rauer S. Qualitative evidence of Ri specific IgG-synthesis in the cerebrospinal fluid from patients with paraneoplastic neurological syndromes. J Neurol Sci. 2008;268:65–8.PubMedView ArticleGoogle Scholar
  122. Stich O, Graus F, Rasiah C, Rauer S. Qualitative evidence of anti-Yo-specific intrathecal antibody synthesis in patients with paraneoplastic cerebellar degeneration. J Neuroimmunol. 2003;141:165–9.PubMedView ArticleGoogle Scholar
  123. Kumar MA, Jain A, Dechant VE, Saito T, Rafael T, Aizawa H, et al. Anti-N-methyl-D-aspartate receptor encephalitis during pregnancy. Arch Neurol. 2010;67:884–7.PubMedView ArticleGoogle Scholar
  124. Tanimura A, Tojyo Y, Turner RJ. Evidence that type I, II, and III inositol 1,4,5-trisphosphate receptors can occur as integral plasma membrane proteins. J Biol Chem. 2000;275:27488–93.PubMedGoogle Scholar
  125. Lischka FW, Zviman MM, Teeter JH, Restrepo D. Characterization of inositol-1,4,5-trisphosphate-gated channels in the plasma membrane of rat olfactory neurons. Biophys J. 1999;76:1410–22.PubMed CentralPubMedView ArticleGoogle Scholar
  126. Vermassen E, Parys JB, Mauger JP. Subcellular distribution of the inositol 1,4,5-trisphosphate receptors: functional relevance and molecular determinants. Biol Cell. 2004;96:3–17.PubMedView ArticleGoogle Scholar
  127. Taylor CW, Dellis O. Plasma membrane IP3 receptors. Biochem Soc Trans. 2006;34:910–2.PubMedView ArticleGoogle Scholar
  128. Dellis O, Dedos SG, Tovey SC, Taufiq Ur R, Dubel SJ, Taylor CW. Ca2+ entry through plasma membrane IP3 receptors. Science. 2006;313:229–33.PubMedView ArticleGoogle Scholar
  129. Iwaki A, Kawano Y, Miura S, Shibata H, Matsuse D, Li W, et al. Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet. 2008;45:32–5.PubMedView ArticleGoogle Scholar
  130. Synofzik M, Beetz C, Bauer C, Bonin M, Sanchez-Ferrero E, Schmitz-Hubsch T, et al. Spinocerebellar ataxia type 15: diagnostic assessment, frequency, and phenotypic features. J Med Genet. 2011;48:407–12.PubMedView ArticleGoogle Scholar
  131. Marelli C, van de Leemput J, Johnson JO, Tison F, Thauvin-Robinet C, Picard F, et al. SCA15 due to large ITPR1 deletions in a cohort of 333 white families with dominant ataxia. Arch Neurol. 2011;68:637–43.PubMed CentralPubMedView ArticleGoogle Scholar
  132. Hara K, Shiga A, Nozaki H, Mitsui J, Takahashi Y, Ishiguro H, et al. Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology. 2008;71:547–51.PubMedView ArticleGoogle Scholar
  133. Huang L, Chardon JW, Carter MT, Friend KL, Dudding TE, Schwartzentruber J, et al. Missense mutations in ITPR1 cause autosomal dominant congenital nonprogressive spinocerebellar ataxia. Orphanet J Rare Dis. 2012;7:67.PubMed CentralPubMedView ArticleGoogle Scholar
  134. Bataller L, Sabater L, Saiz A, Serra C, Claramonte B, Graus F. Carbonic anhydrase-related protein VIII: autoantigen in paraneoplastic cerebellar degeneration. Ann Neurol. 2004;56:575–9.PubMedView ArticleGoogle Scholar
  135. Hoftberger R, Sabater L, Velasco F, Ciordia R, Dalmau J, Graus F. Carbonic anhydrase-related protein VIII antibodies and paraneoplastic cerebellar degeneration. Neuropathol Appl Neurobiol. 2014;40:650–3.PubMed CentralPubMedView ArticleGoogle Scholar
  136. Aspatwar A, Tolvanen ME, Parkkila S. Phylogeny and expression of carbonic anhydrase-related proteins. BMC Mol Biol. 2010;11:25.PubMed CentralPubMedView ArticleGoogle Scholar
  137. Kato K. Sequence of a novel carbonic anhydrase-related polypeptide and its exclusive presence in Purkinje cells. FEBS Lett. 1990;271:137–40.PubMedView ArticleGoogle Scholar
  138. Skaggs LA, Bergenhem NC, Venta PJ, Tashian RE. The deduced amino acid sequence of human carbonic anhydrase-related protein (CARP) is 98 % identical to the mouse homologue. Gene. 1993;126:291–2.PubMedView ArticleGoogle Scholar
  139. Nogradi A, Jonsson N, Walker R, Caddy K, Carter N, Kelly C. Carbonic anhydrase II and carbonic anhydrase-related protein in the cerebellar cortex of normal and lurcher mice. Brain Res Dev Brain Res. 1997;98:91–101.PubMedView ArticleGoogle Scholar
  140. Lakkis MM, O’Shea KS, Tashian RE. Differential expression of the carbonic anhydrase genes for CA VII (Car7) and CA-RP VIII (Car8) in mouse brain. J Histochem Cytochem. 1997;45:657–62.PubMedView ArticleGoogle Scholar
  141. Taniuchi K, Nishimori I, Takeuchi T, Fujikawa-Adachi K, Ohtsuki Y, Onishi S. Developmental expression of carbonic anhydrase-related proteins VIII, X, and XI in the human brain. Neuroscience. 2002;112:93–9.PubMedView ArticleGoogle Scholar
  142. Turkmen S, Guo G, Garshasbi M, Hoffmann K, Alshalah AJ, Mischung C, et al. CA8 mutations cause a novel syndrome characterized by ataxia and mild mental retardation with predisposition to quadrupedal gait. PLoS Genet. 2009;5:e1000487.PubMed CentralPubMedView ArticleGoogle Scholar
  143. Najmabadi H, Hu H, Garshasbi M, Zemojtel T, Abedini SS, Chen W, et al. Deep sequencing reveals 50 novel genes for recessive cognitive disorders. Nature. 2011;478:57–63.PubMedView ArticleGoogle Scholar
  144. Jiao Y, Yan J, Zhao Y, Donahue LR, Beamer WG, Li X, et al. Carbonic anhydrase-related protein VIII deficiency is associated with a distinctive lifelong gait disorder in waddles mice. Genetics. 2005;171:1239–46.PubMed CentralPubMedView ArticleGoogle Scholar
  145. Hirasawa M, Xu X, Trask RB, Maddatu TP, Johnson BA, Naggert JK, et al. Carbonic anhydrase related protein 8 mutation results in aberrant synaptic morphology and excitatory synaptic function in the cerebellum. Mol Cell Neurosci. 2007;35:161–70.PubMed CentralPubMedView ArticleGoogle Scholar
  146. Kelly C, Nogradi A, Walker R, Caddy K, Peters J, Carter N. Lurching, reeling, waddling and staggering in mice—is carbonic anhydrase (CA) VIII a candidate gene? Biochem Soc Trans. 1994;22:359S.PubMedView ArticleGoogle Scholar
  147. Sabater L, Bataller L, Carpentier AF, Aguirre-Cruz ML, Saiz A, Benyahia B, et al. Protein kinase Cgamma autoimmunity in paraneoplastic cerebellar degeneration and non-small-cell lung cancer. J Neurol Neurosurg Psychiatry. 2006;77:1359–62.PubMed CentralPubMedView ArticleGoogle Scholar
  148. Hoftberger R, Kovacs GG, Sabater L, Nagy P, Racz G, Miquel R, et al. Protein kinase Cgamma antibodies and paraneoplastic cerebellar degeneration. J Neuroimmunol. 2013;256:91–3.PubMedView ArticleGoogle Scholar
  149. Sugiyama N, Hamano S, Mochizuki M, Tanaka M, Takahashi Y. A case of chronic cerebellitis with anti-glutamate receptor delta 2 antibody. No To Hattatsu. 2004;36:60–3.PubMedGoogle Scholar
  150. Shimokaze T, Kato M, Yoshimura Y, Takahashi Y, Hayasaka K. A case of acute cerebellitis accompanied by autoantibodies against glutamate receptor delta2. Brain Dev. 2007;29:224–6.PubMedView ArticleGoogle Scholar
  151. Shiihara T, Kato M, Konno A, Takahashi Y, Hayasaka K. Acute cerebellar ataxia and consecutive cerebellitis produced by glutamate receptor delta2 autoantibody. Brain Dev. 2007;29:254–6.PubMedView ArticleGoogle Scholar
  152. Jarius S, Martinez-Garcia P, Hernandez AL, Brase JC, Borowski K, Regula JU, et al. Two new cases of anti-Ca (anti-ARHGAP26/GRAF) autoantibody-associated cerebellar ataxia. J Neuroinflammation. 2013;10:7.PubMed CentralPubMedView ArticleGoogle Scholar
  153. Doss S, Numann A, Ziegler A, Siebert E, Borowski K, Stocker W, et al. Anti-Ca/anti-ARHGAP26 antibodies associated with cerebellar atrophy and cognitive decline. J Neuroimmunol. 2014;267:102–4.PubMedView ArticleGoogle Scholar
  154. Vernino S, Lennon VA. New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity. Ann Neurol. 2000;47:297–305.PubMedView ArticleGoogle Scholar
  155. Lennon VA, Kryzer TJ, Griesmann GE, O’Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332:1467–74.PubMedView ArticleGoogle Scholar
  156. Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al. Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain. 1997;120(Pt 8):1279–300.PubMedView ArticleGoogle Scholar
  157. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. ncidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. J Neurol Sci. 1997;147:35–42.Google Scholar
  158. Greenlee JE, Brashear HR. Antibodies to cerebellar Purkinje cells in patients with paraneoplastic cerebellar degeneration and ovarian carcinoma. Ann Neurol. 1983;14:609–13.PubMedView ArticleGoogle Scholar
  159. Peterson K, Rosenblum MK, Kotanides H, Posner JB. Paraneoplastic cerebellar degeneration. I. A clinical analysis of 55 anti-Yo antibody-positive patients. Neurology. 1992;42:1931–7.PubMedView ArticleGoogle Scholar
  160. Greenlee JE, Clawson SA, Hill KE, Wood BL, Tsunoda I, Carlson NG. Purkinje cell death after uptake of anti-Yo antibodies in cerebellar slice cultures. J Neuropathol Exp Neurol. 2010;69:997–1007.PubMed CentralPubMedView ArticleGoogle Scholar
  161. Darnell RB, Posner JB. Paraneoplastic syndromes. Oxford, New York: Oxford University Press; 2011.Google Scholar
  162. Eichler TW, Totland C, Haugen M, Qvale TH, Mazengia K, Storstein A, et al. CDR2L Antibodies: a new player in paraneoplastic cerebellar degeneration. PLoS One. 2013;8:e66002.PubMed CentralPubMedView ArticleGoogle Scholar
  163. Darnell RB, Furneaux HM, Posner JB. Characterization of antigens bound by CSF and serum of a patient with cerebellar degeneration: co-expression in Purkinje cells and tumor lines of neuroectodermal origin. Neurology. 1989;39(Suppl):260.Google Scholar
  164. Darnell RB, Furneaux HM, Posner JB. Antiserum from a patient with cerebellar degeneration identifies a novel protein in Purkinje cells, cortical neurons, and neuroectodermal tumors. J Neurosci. 1991;11:1224–30.PubMedGoogle Scholar
  165. Trotter JL, Hendin BA, Osterland CK. Cerebellar degeneration with Hodgkin disease. An immunological study. Arch Neurol. 1976;33:660–1.PubMedView ArticleGoogle Scholar
  166. Graus F, Dalmau J, Valldeoriola F, Ferrer I, Rene R, Marin C, et al. Immunological characterization of a neuronal antibody (anti-Tr) associated with paraneoplastic cerebellar degeneration and Hodgkin’s disease. J Neuroimmunol. 1997;74:55–61.PubMedView ArticleGoogle Scholar
  167. Bernal F, Shams’ili S, Rojas I, Sanchez-Valle R, Saiz A, Dalmau J, et al. Anti-Tr antibodies as markers of paraneoplastic cerebellar degeneration and Hodgkin’s disease. Neurology. 2003;60:230–4.PubMedView ArticleGoogle Scholar
  168. Probst C, Komorowski L, de Graaff E, van Coevorden-Hameete M, Rogemond V, Honnorat J, et al. Standardized test for anti-Tr/DNER in patients with paraneoplastic cerebellar degeneration. Neurol Neuroimmunol Neuroinflamm. 2015;2:e68.PubMed CentralPubMedView ArticleGoogle Scholar
  169. de Graaff E, Maat P, Hulsenboom E, van den Berg R, van den Bent M, Demmers J, et al. Identification of delta/notch-like epidermal growth factor-related receptor as the Tr antigen in paraneoplastic cerebellar degeneration. Ann Neurol. 2012;71:815–24.PubMedView ArticleGoogle Scholar
  170. Pittock SJ, Lucchinetti CF, Parisi JE, Benarroch EE, Mokri B, Stephan CL, et al. Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol. 2005;58:96–107.PubMedView ArticleGoogle Scholar
  171. Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blocker IM, et al. Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology. 2014;82:1521–8.PubMedView ArticleGoogle Scholar
  172. Boronat A, Gelfand JM, Gresa-Arribas N, Jeong H-Y, Walsh M, Roberts K, et al. Encephalitis and antibodies to DPPX, a subunit of Kv4.2 potassium channels. Ann Neurol. 2012; in press (doi:https://doi.org/10.1002/ana.23756).
  173. Stoeck K, Carstens P, Jarius S, Raddatz D, Stöcker W, Wildemann B, et al. Prednisolone and azathioprine are effective in DPPX antibody–positive autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2015;2:e86.PubMed CentralPubMedView ArticleGoogle Scholar
  174. Tobin WO, Lennon VA, Komorowski L, Probst C, Clardy SL, Aksamit AJ, et al. DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients. Neurology. 2014;83:1797–803.PubMedPubMed CentralView ArticleGoogle Scholar
  175. Becker EB, Zuliani L, Pettingill R, Lang B, Waters P, Dulneva A, et al. Contactin-associated protein-2 antibodies in non-paraneoplastic cerebellar ataxia. J Neurol Neurosurg Psychiatry. 2012;83:437–40.PubMed CentralPubMedView ArticleGoogle Scholar
  176. Balint B, Regula JU, Jarius S, Wildemann B. Caspr2 antibodies in limbic encephalitis with cerebellar ataxia, dyskinesias and myoclonus. J Neurol Sci. 2013;327:73–4.PubMedView ArticleGoogle Scholar
  177. Steriade C, Day GS, Lee L, Murray BJ, Fritzler MJ, Keith J. LGI1 autoantibodies associated with cerebellar degeneration. Neuropathol Appl Neurobiol. 2014;40:645–9.PubMedView ArticleGoogle Scholar
  178. Honnorat J, Saiz A, Giometto B, Vincent A, Brieva L, de Andres C, et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol. 2001;58:225–30.PubMedView ArticleGoogle Scholar
  179. Piccolo G, Tavazzi E, Cavallaro T, Romani A, Scelsi R, Martino G. Clinico-pathological findings in a patient with progressive cerebellar ataxia, autoimmune polyendocrine syndrome, hepatocellular carcinoma and anti-GAD autoantibodies. J Neurol Sci. 2010;290:148–9.PubMedView ArticleGoogle Scholar
  180. Kono S, Miyajima H, Sugimoto M, Suzuki Y, Takahashi Y, Hishida A. Stiff-person syndrome associated with cerebellar ataxia and high glutamic acid decarboxylase antibody titer. Intern Med. 2001;40:968–71.PubMedView ArticleGoogle Scholar
  181. Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, et al. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131:2553–63.PubMedView ArticleGoogle Scholar
  182. Malik S, Furlan AJ, Sweeney PJ, Kosmorsky GS, Wong M. Optic neuropathy: a rare paraneoplastic syndrome. J Clin Neuroophthalmol. 1992;12:137–41.PubMedGoogle Scholar
  183. Antoine JC, Honnorat J, Vocanson C, Koenig F, Aguera M, Belin MF, et al. Posterior uveitis, paraneoplastic encephalomyelitis and auto-antibodies reacting with developmental protein of brain and retina. J Neurol Sci. 1993;117:215–23.PubMedView ArticleGoogle Scholar
  184. Yu Z, Kryzer TJ, Griesmann GE, Kim K, Benarroch EE, Lennon VA. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol. 2001;49:146–54.PubMedView ArticleGoogle Scholar
  185. Mader S, Gredler V, Schanda K, Rostasy K, Dujmovic I, Pfaller K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation. 2011;8:184.PubMed CentralPubMedView ArticleGoogle Scholar
  186. Reindl M, Di Pauli F, Rostasy K, Berger T. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol. 2013;9:455–61.PubMedView ArticleGoogle Scholar
  187. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol. 2010;6:383–92.PubMedView ArticleGoogle Scholar
  188. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation. 2012;9:14.PubMed CentralPubMedView ArticleGoogle Scholar
  189. Lucchinetti CF, Kimmel DW, Lennon VA. Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology. 1998;50:652–7.PubMedView ArticleGoogle Scholar
  190. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124:1138–48.PubMedView ArticleGoogle Scholar
  191. Dalmau J, Graus F, Rosenblum MK, Posner JB. Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore). 1992;71:59–72.View ArticleGoogle Scholar
  192. Budde-Steffen C, Anderson NE, Rosenblum MK, Graus F, Ford D, Synek BJ, et al. An antineuronal autoantibody in paraneoplastic opsoclonus. Ann Neurol. 1988;23:528–31.PubMedView ArticleGoogle Scholar
  193. Pittock SJ, Lucchinetti CF, Lennon VA. Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. Ann Neurol. 2003;53:580–7.PubMedView ArticleGoogle Scholar
  194. Chan KH, Vernino S, Lennon VA. ANNA-3 anti-neuronal nuclear antibody: marker of lung cancer-related autoimmunity. Ann Neurol. 2001;50:301–11.PubMedView ArticleGoogle Scholar
  195. Bataller L, Wade DF, Fuller GN, Rosenfeld MR, Dalmau J. Cerebellar degeneration and autoimmunity to zinc-finger proteins of the cerebellum. Neurology. 2002;59:1985–7.PubMedView ArticleGoogle Scholar
  196. Bataller L, Wade DF, Graus F, Stacey HD, Rosenfeld MR, Dalmau J. Antibodies to Zic4 in paraneoplastic neurologic disorders and small-cell lung cancer. Neurology. 2004;62:778–82.PubMed CentralPubMedView ArticleGoogle Scholar
  197. Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau J, Graus F. ZIC antibodies in paraneoplastic cerebellar degeneration and small cell lung cancer. J Neuroimmunol. 2008;201–202:163–5.PubMed CentralPubMedView ArticleGoogle Scholar
  198. Graus F, Vincent A, Pozo-Rosich P, Sabater L, Saiz A, Lang B, et al. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplastic neurological syndromes. J Neuroimmunol. 2005;165:166–71.PubMed CentralPubMedView ArticleGoogle Scholar
  199. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. SOX antibodies in small-cell lung cancer and Lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27:4260–7.PubMedView ArticleGoogle Scholar
  200. Hoffmann LA, Jarius S, Pellkofer HL, Schueller M, Krumbholz M, Koenig F, et al. Anti-Ma and anti-Ta associated paraneoplastic neurological syndromes: 22 newly diagnosed patients and review of previous cases. J Neurol Neurosurg Psychiatry. 2008;79:767–73.PubMedView ArticleGoogle Scholar
  201. Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B, et al. Clinical analysis of anti-Ma2-associated encephalitis. Brain. 2004;127:1831–44.PubMedView ArticleGoogle Scholar
  202. Fritzler MJ, Zhang M, Stinton LM, Rattner JB. Spectrum of centrosome autoantibodies in childhood varicella and post-varicella acute cerebellar ataxia. BMC Pediatr. 2003;3:11.PubMed CentralPubMedView ArticleGoogle Scholar
  203. Cimolai N, Mah D, Roland E. Anticentriolar autoantibodies in children with central nervous system manifestations of Mycoplasma pneumoniae infection. J Neurol Neurosurg Psychiatry. 1994;57:638–9.PubMed CentralPubMedView ArticleGoogle Scholar
  204. Hadjivassiliou M, Aeschlimann P, Strigun A, Sanders DS, Woodroofe N, Aeschlimann D. Autoantibodies in gluten ataxia recognize a novel neuronal transglutaminase. Ann Neurol. 2008;64:332–43.PubMedView ArticleGoogle Scholar
  205. McKeon A, Lennon VA, Pittock SJ, Kryzer TJ, Murray J. The neurologic significance of celiac disease biomarkers. Neurology. 2014;83:1789–96.PubMedPubMed CentralView ArticleGoogle Scholar
  206. Uchibori A, Sakuta M, Kusunoki S, Chiba A. Autoantibodies in postinfectious acute cerebellar ataxia. Neurology. 2005;65:1114–6.PubMedView ArticleGoogle Scholar
  207. Storstein A, Knudsen A, Vedeler CA. Proteasome antibodies in paraneoplastic cerebellar degeneration. J Neuroimmunol. 2005;165:172–8.PubMedView ArticleGoogle Scholar
  208. Ichikawa H, Susuki K, Yuki N, Kawamura M. Ataxic form of Guillain-Barre syndrome associated with anti-GD1b IgG antibody. Rinsho Shinkeigaku. 2001;41:523–5.PubMedGoogle Scholar
  209. Araki T, Nakata H, Kusunoki S, Arai Y, Katayama Y. Immunoadsorption therapy with TR-350 (tryptophan column) for Guillain-Barre syndrome: investigation including serum antiganglioside antibody assay. Rinsho Shinkeigaku. 2000;40:979–85.PubMedGoogle Scholar
  210. Kaida K, Kamakura K, Ogawa G, Ueda M, Motoyoshi K, Arita M, et al. GD1b-specific antibody induces ataxia in Guillain-Barre syndrome. Neurology. 2008;71:196–201.PubMedView ArticleGoogle Scholar
  211. Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N: Ataxic Guillain-Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J Neurol Neurosurg Psychiatry 2011, 82:294-299.Google Scholar
  212. Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 2: Anti-PKC-gamma, anti-GluR-delta2, anti-Ca/ARHGAP26 and anti-VGCC. J Neuroinflammation. 2015, 12:167.Google Scholar
  213. Jarius S, Wildemann B. ‘Medusa head ataxia’: the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook. J Neuroinflammation. 2015, 12: 168.Google Scholar

Copyright

© Jarius and Wildemann. 2015